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ABSTRACT 
 
 Cleft palate (CP) is one of the most common birth defects. It may not be life 
threatening but many functions, such as feeding, digestion, speech, middle-ear 
ventilation, hearing, respiration, and facial and dental development, can be disturbed 
because of the structures involved.  These problems can also cause emotional, 
psychosocial, and educational difficulties. It imposes a tremendous health burden and 
often leaves lasting disfigurement. In humans and mice, the secondary palate forms from 
outgrowths of neural crest-derived mesenchyme covered with a double layer of epithelial 
cells. The shelves elevate over the tongue and grow toward each other. The medial edge 
epithelium (MEE) adheres to form the medial epithelial seam (MES). MES cells then 
undergo epithelial to mesenchymal transition (EMT), cell apoptosis or migrate to the 
oral and nasal surfaces to form a mesenchymal cell confluence. 
 This fusion process requires transforming growth factor β3 (TGFβ3), and blocking 
the expression of this protein or its downstream signaling cascade results in CP. 
 Eph receptors tyrosine kinases and their ephrin ligands are responsible for multiple 
developmental events such as adhesion and migration. Binding of ephrins to Ephs on 
opposing cells causes tyrosine kinase activation in the Eph- bearing cells (forward 
signaling), while binding of Ephs can activate intracellular signaling inside ephrin-
bearing cells (reverse signaling). Activation of ephrin reverse signaling in chicken 
palates induces fusion, and it requires phosphatidylinositol-3 kinase (PI3K). Blockage of 
reverse signaling inhibited TGFβ3 induced fusion in the chicken and natural fusion in 
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the mouse palate. Thus, ephrin reverse signaling is necessary to induce palate fusion 
independent of TGFβ3. 
  EMT is orchestrated by a complex network of signaling molecules and it is a 
critical step for palatal fusion. TGFβ family is a multifunctional cytokine that oversees 
and directs all aspects of cell development, differentiation and survival of essentiall cell 
types and tissues. Also, it is a suppressor of cell growth and proliferation particularly in 
tumor cells of epithelial and mesenchymal origins. 
 Ephrin signaling promotes elevation of TGFβ signaling. These findings lead to the 
central hypothesis that the TGFβ and Eph/ephrin pathways cooperate in EMT in palatal 
fusion. Thus, the goal of this research project is to use the palate model system to 
generate cellular responses and changes to study the basic mechanisms that control EMT 
during palatogenesis. 
 Therefore the aims of this work are as follows: a) Determine if Eph and ephrins 
play a role in palatal fusion and b) Establish if ephrin reverse signaling is necessary and 
sufficient to induce EMT in palatal fusion independent of TGFβ. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW* 
 
Orofacial clefts are the most prevalent craniofacial birth defects and the second 
most common birth anomaly (1). Among of all the possible craniofacial defects observed 
in newborns; perhaps the most well-known defect is the Cleft palate (CP) (2). Occurring 
with a frequency of approximately 1 in every 700 births per year in the US, the incidence 
of CP is equal to 475 cleft palates per month or 15 clefts per day (3,4). In other words, 
1% of infants born worldwide (1 million) each year exhibit some form of facial 
dysmorphology, but the most dramatic observation is that in this country alone, a baby is 
born with a facial cleft every hour, of every day of the year (5). 
Clefts of the palate (CP) and the lip (CLP) require a complex multidisciplinary 
treatment and having lifelong implications for affected individuals. In the United States 
of America, $100,000 is the amount estimated to be to rehabilitate a child born with an 
oral cleft.  
The approach of the patient with cleft lip (CL) and palate requires a team that 
should be ideally composed by craniofacial surgeons, otolaryngologists, geneticists, 
anesthesiologists, speech-language pathologists, nutritionists, orthodontists, 
                                                
 
*Reprinted with permission from “Cleft Lip and Palate Genetics and Application in 
Early Embryological Development” by Yu W, Serrano M, Miguel SS, Ruest LB, 
Svoboda KK, 2009, Indian Journal of Plastic Surgery, 42 Suppl, S35-S50, Copyright 
2009 by Indian Journal of Plastic Surgery. 
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prosthodontists, and psychologists, and to be capable of treating even rare facial clefts 
with excellence, neurosurgeons, and ophthalmologists (6). In this manner, it is possible 
to provide long-term follow up through the entire child’s development and achieve all of 
the following treatment goals: facial aesthetic, integrity of the primary and secondary 
palate, normal speech and hearing, class I occlusion with normal masticatory function, 
good dental and periodontal health, and normal psychosocial development (6,7). 
 
Palate Development 
The palatal structures are composed of the cranial neural crest (CNC)-derived 
mesenchyme and pharyngeal ectoderm (8-11). The epithelia that cover the palatal 
shelves are regionally divided into oral, nasal and medial edge epithelia (MEE). The 
nasal and oral epithelia differentiate into pseudostratified and squamous epithelia, 
whereas the MEE is removed from the fusion line (12) (Fig. 1-1). 
The secondary palate originates as an outgrowth of the maxillary prominences at 
approximately embryonic day 11.5 in the mouse (E11.5-m) (Fig. 1-1) and post coital 6 
weeks in humans (p.c.6wk-h). The palate shelves initially grow vertically along the sides 
of the tongue (E13.5-m; p.c.7wk-h) and then rise above the tongue as the latter drops in 
the oral cavity due to the forward and downward growth of the mandible (E14.0-m; 
p.c.8wks-h). With continued growth, the shelves appose at the midline (E14.5-m; 
p.c.10wks-h) and eventually fuse (E15.5-m; p.c.13wk-h) (13). Numerous genes that are 
similar in mice (14) and humans (13,15,16) are expressed (Table 1and 2) during palatal 
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development (12). Some of the cleft palate are also associate with other birth defects 
syndromes (Table 1) while others occur independently (Table 2). 
During fusion, the epithelium covering the tip of the opposing palatal shelves 
adheres, intercalates and thins into a single-layer midline epithelial seam (MES) (10). 
The disintegration of this seam results in the confluence of the palatal mesenchyme. 
Tremendous interest has arisen in the cellular mechanisms underlying MES degradation. 
Epithelial-mesenchymal transition (EMT) is one of the proposed models that regulate the 
medial edge epithelial (MEE) cell fate (10,17-24). However, other mechanisms have 
been proposed, such as apoptosis (25-28), in which all MEE cells are theorized to die 
during fusion (12). Alternatively, it is hypothesized by some researchers that MES cells 
disappear by migrating from the midline towards the nasal and oral epithelia (29,30). 
Other investigators postulate that all events, including apoptosis, migration and EMT, 
may occur (10,27,31). Interestingly, the fusion of the external surface of the bilateral 
maxillary processes with the nasofrontal prominence in the chick is similar to palatal 
fusion (Fig. 1-2) (32). The outer periderm layer dies through apoptosis, and the lateral 
edge epithelium of the intermaxillary segment of the nasofrontal process fuses with the 
medial edge epithelium of the external maxillary process to form a seam that transitions 
to a confluent mesenchyme (Fig. 1-2) (32,33).  
 
Molecular Genetics Behind Cleft Palate  
Much of the general understanding of the genetic control of palate development 
has been derived from mouse genetic studies. This is largely due to the striking 
  4 
similarity between palate development in humans and mice. In addition, the chick is a 
classical experimental embryology model system in which palate morphogenesis has 
been characterized (12,34-37). The understanding of the molecular causes of CP is 
complicated due to the amount of factors that can, when mutated, result in various forms 
of clefting (38). 
TGFβ3 
TGFβ3 is a member of the TGFβ superfamily expressed in the medial edge 
epithelial (MEE) cells before fusion of the palatal shelves. TGFβ3 is required for palatal 
shelf fusion (34,38,39), as evidenced by homozygous TGFβ3 null mice newborns, which 
have a cleft secondary palate. The function for TGFβ3 in palatogenesis relates to 
regulation of the breakdown of epithelial cells that lie between the palatal shelves (40). 
In the TGFβ3-null mice, the palatal shelves appear to approximate and adhere, but the 
epithelial seam remains preventing fusion (38). The TGFβ signaling pathway is initiated 
by ligand-induced heterotetramerization of a type I receptor dimer and a type II receptor 
dimer. Activated type I receptors phosphorylate R-Smads such as Smad2, which then 
partner with the obligate common mediator Smad4 to regulate transcription. Knockdown 
of Smad2 function in palatal explant cultures resulted in a failure of MES degeneration, 
and transgenic overexpression of Smad2 in the palatal epithelium partially rescued palate 
fusion in TGFβ3–/– mice (12,40). TGFβ signaling can activate other intracellular signal 
transduction pathways, including p38 MAPK. The activation of p38 MAPK is elevated 
in the epithelium of the fusing palatal shelves (41). The treatment of K14-Cre; Smad4f/f 
palatal explants with a p38 MAPK inhibitor was able to block TGFβ-dependent 
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expression of the p21 (Cdkn1a) cyclin-dependent kinase inhibitor gene in the MES, 
which correlated with reduced apoptosis and failed MES dissolution. These results 
indicate that Smad- and p38 MAPK-dependent mechanisms are functionally redundant 
during palate fusion (12,41).  
Previous studies had shown that TGFβR3 is expressed in the epithelium and was 
specifically localized to the MEE during palatal shelf fusion in mice (42). Knockdown of 
TGFβr3 with siRNA in a palatal shelf culture model inhibited in vitro palatal shelf 
fusion due to persistence of the palatal epithelium (43,44). Recent findings demonstrated 
a partial rescue of the CP phenotype in Wnt1-Cre; TGFβr2 F/F;TGFβr3+/- mice 
suggesting that TGFβR3 played a pivotal role in maintaining homeostasis of TGFβ 
signaling during palatal vascular and bone development (44,45).  
Ephs and Ephrins 
 Eph/ephrin family members have been demonstrated to control anterior palatal 
shelf outgrowth (46). These signaling molecules have the capacity for bidirectional 
signaling, such that a forward signal can be transduced into the cell in which the Eph 
receptor tyrosine kinase is expressed, and a reverse signal can be transduced into the cell 
in which the ephrin (Efn) is expressed. The Efnb1 gene exhibits a highly restricted 
expression pattern in the anterior palatal mesenchyme during all stages of palatogenesis, 
and Efnb1-null mice and Efnb1+/– heterozygous females exhibit CP accompanied by 
decreased cell proliferation in the anterior palatal mesenchyme (47). Mice carrying a 
series of targeted point mutations that specifically abrogate reverse signaling while 
leaving forward signaling by ephrin B1 intact revealed that reverse signaling is 
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dispensable for palatogenesis (47). This study also showed that ephrin reverse signaling 
using EphB2 is required and sufficient for chicken palate (47). 
Null mutations in the EphB2 and EphB3 receptors, or specific disruption of 
forward signaling through these receptors, also resulted in reduced palatal shelf 
proliferation and CP (48,49). 
PDGF Signaling 
Platelet-derived growth factor (PDGF) and its receptors (PDGFRα and -β) have 
specific roles in promoting tissue-tissue interactions to control cell migration, 
proliferation and survival during embryonic development (50). Deletion of Pdgfrα in the 
neural crest leads to defects in palatal fusion, nasal septation and abnormal development 
of several facial bones and cartilage structures in mouse models. Pdgfc-null neonates 
have a complete cleft of the secondary palate, accompanied by failure of the palatal 
bones to extend across the roof of the oronasal cavity (51). 
Wingless Type (Wnt) Protein Signaling 
Wnt pathway activity is specifically localized to facial epithelia and underlying 
mesenchyme in the lateral nasal, maxillary and mandibular prominences. In neural crest 
mesenchyme, Wnts promote proliferation; thus, promoting the growth of the maxillary 
prominences that come together to form the palate (52). In the facial epithelium, 
expression of multiple Wnts is essential for the fusion of facial prominences (53). Some 
abnormalies are linked to disruptions in various Wnt genes (54). Some perturbations of 
the pathway produce mild to severe facial clefting in various animal models as well as in 
humans (55). Mutation of Wnt9b in mice leads to CLP (54). Abnormal expression of the 
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lipoprotein receptor-related protein 6, Lrp6, a Wnt pathway coreceptor, also results in 
CLP. 
Irf 6 (Interferon Regulatory Factor 6) 
Irf6 is a member of a large family of transcription factors that bind to specific 
DNA sequences and regulate gene expression. In mice, disruption of this gene results in 
clefting (38). In humans, mutations in IRF6 have been shown to cause Van Der Woude 
syndrome and popliteal ptyergium syndrome, two disorders that are characterized by the 
presence of CP. Variations in IRF6 increased the risk for isolated CLP (56). Irf6 Irf6 
mutant mice exhibit a hyper-proliferative oral epithelium that fails to undergo terminal 
differentiation, causing epithelial adhesions that occlude the oral cavity and result in CP 
(57). Taken together, these data suggest Irf6 mutations may result in defective elevation 
of palatine shelves, secondary to inappropriate adhesions with oral epithelium (38). 
VAX1  
VAX1 gene is a member of the Emx/Not gene family and encodes a 
transcriptional regulator with a DNA-binding homeobox domain. Single nucleotide 
polymorphisms in the VAX1 genes were overrepresented in patients with CLP, 
suggesting that variants in VAX1 itself may contribute to development of clefting. 
Mouse knockouts for Vax1 show CP, and this gene was expressed widely in developing 
craniofacial structures (58). Therefore, variants in VAX1 are strong candidates in the 
etiopathogenesis of  CLP. 
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ADAMTS Family Metalloproteases 
Recent studies suggest that extracellular matrix (ECM) proteins participate in the 
regulation of palatal growth. Simultaneous disruption of the genes encoding two 
ADAMTS family metalloproteases, Adamts9 and Adamts20, resulted in CP with defects 
in early outgrowth, elevation and approximation of the palatal shelves (59). These 
secreted metalloproteases bind to the cell surface where they are actively involved in 
pericellular ECM proteolysis. A major substrate for these proteases is versican, a 
proteoglycan with space-filling properties. The cleavage of versican was indeed reduced 
in Adamts9+/–; Adamts20 bt/bt compound mutants. Interestingly, simultaneous disruption 
of versican and Adamts20 function also resulted in reduced palatal cell proliferation 
(59). It is possible that proteolysis of ECM molecules such as versican might produce 
bioactive fragments with growth-promoting activity.  
Fibroblast Growth Factor 10 (Fgf10)  
Fgf10 it is a crucial mesenchymal signal that is required for palatal outgrowth. 
Mice homozygous for a null mutation in either Fgf10 or the gene encoding its receptor, 
fibroblast growth factor receptor 2b (Fgfr2b), exhibited CP with impaired palatal shelf 
outgrowth (60). Expression of Fgf10 mRNA was restricted to the mesenchyme, but 
Fgfr2b mRNA was detected in the overlying epithelium. Fgfr2 function is required 
within the epithelium, mice having a epithelial-specific deletion of Fgfr2 also exhibited 
CP (61). Both epithelial and mesenchymal cell proliferation were reduced in the absence 
of either Fgf10 or Fgfr2b. Thus, suggesting the presence of a factor that signals from the 
epithelium back to the underlying mesenchyme dependent on Fgf10/Fgfr2b signaling.  
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The expression of Fgf10 was also reduced in the palatal mesenchyme of embryos 
lacking mesenchymal Smo, indicating that Shh and Fgf10 function in a positive-
feedback loop that drives the outgrowth of the palatal shelves. 
FOXE1 (Forkhead Box Protein E1) 
 FOXE1 is a forkhead containing transcription factor that is involved in 
embryonic pattern formation. The FOXE1 gene is expressed at the point of fusion 
between maxillary and nasal processes during palatogenesis. Positional cloning and 
candidate gene sequencing show a correlation between mutations in FOXE1 and the 
occurrence of CLP (62). FOXE1 is expressed in the secondary palate epithelium of both 
mice and human embryos (63). Mice with a null mutation in FOXE1 have CP (64). 
 
Molecular Signaling Events in Embryonic Palatal Development 
As stated above, CP with or without CL is a complex trait triggered by a 
combination of numerous genes and environmental factors (65,66). The palatal shelf 
development defects will be divided in five categories: failure of palatal shelf formation, 
fusion of the palatal shelf with the tongue or mandible, failure of palatal elevation, 
failure of palatal shelves to meet after elevation, persistence of middle edge epithelium. 
Failure of Palatal Shelf Formation 
The failure of palatal shelf formation is a rare severe defect. Recent studies have 
identified several molecular networks operating between the palatal shelf epithelium and 
mesenchyme during different steps of palatogenenesis. These networks include signaling 
molecules and growth factors such as sonic hedge hog (Shh), members of the 
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transforming growth factor β (TGFβ) super family, including bone morphogenetic 
proteins (Bmps) and TGFβs, fibroblast growth factors and their receptors (FgfR), 
effectors and targets (13,67). Studies addressing the role of Fgf signaling during early 
palatal development by analyzing Fgf10 and FgfR2b mutants found altered cell 
proliferation within both mesenchyme and epithelium in the palatal shelves and 
increased apoptosis within the epithelium. Fgf10 and FgfR2b mutations affected the 
initial development of palatal shelves, and the mouse pups had complete CP (68). By 
signaling via its receptor, FgfR2b, in the palatal shelf epithelium, the mesenchymal 
derived Fgf10 supports epithelial proliferation and survival and also induces the 
expression of Shh within the epithelium. Shh, in turn, signals to the mesenchyme and 
stimulates cell proliferation. In general, the signaling activities are subject to tight 
spatiotemporal control, and, in many instances, too much or too control little is 
detrimental to the developing organ (12).  
This situation is well illustrated in anomalies caused by deregulated hedgehog 
(hh) and Fgf signaling (69,70). While Fgf10/FgfR2b activity plays a crucial role during 
palatogenenesis, it appears to be subject to the tight spatiotemporal regulation shown in 
mice lacking Shox2. Shox2 mutant mice develop a very rare type of CP that may also be 
found in humans (36): the soft palate is intact whereas, the hard palate has a cleft. 
Abnormal proliferation and apoptosis were theorized to be the cause of the cleft. 
Surprisingly, a number of protagonists implicated in palatogenesis, including Msx1, 
Bmp4, Pax9, Lhx8, Osr2, TGFβ3 and Jag 2, were expressed normally (36). In contrast, 
Fgf10 and Fgfr2b were expressed at ectopic sites within the mesenchyme of the Shox2 
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mutant mice (71). These studies emphasize the importance of the precise timing and 
determination of sites of signaling activities necessary for normal development. The 
mutation of activin-βA causes a severe facial primordial development defect, which may 
be responsible for the retardation of palatal shelf development and complete CP. In 
addition, other genes, including Msx1, Lhx8, Shox2 and Osr2, assume important roles in 
the palatal shelf growth. The targeted mutation of these genes in mice generates CP, 
indicating the intrinsic requirement of these factors during palatogenesis (71). 
Fusion of the Palatal Shelf with the Tongue or Mandible 
Under normal conditions, palatal shelves do not fuse with other oral structures. 
However, in mice that do not express Fgf10, the palatal shelf epithelium fuses with the 
tongue and mandible (68). The loss of function mutations of Fgf10 results in anterior 
palatal shelf fusion with the tongue, whereas the middle and posterior palatal shelf 
regions adhere to the mandible, thus preventing the elevation of the palatal shelf (72). 
There is a severe reduction of the expression of Jagged 2, thereby encoding a ligand for 
the Notch family receptors and ectopic TGFβ3 production in the nasal epithelia of these 
mice. The analysis of Jag2 mutant embryos indicates that Jag2-Notch signaling prevents 
inappropriate palatal shelf adhesion to other oral epithelia through the control of oral 
epithelial differentiation. Mutations in TBX22 have been reported in families with X-
linked CP and ankiloglossia (73-75). Tbx22 is expressed in the developing palate and 
tongue in mice, suggesting an important role in regulating tongue and palate 
development. 
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Failure of Palatal Elevation 
Palatal shelf elevation is a rapid movement triggered by both intrinsic forces 
within the palatal shelves proper and by influences from other craniofacial and oral 
structures, including the movement of the tongue, and growth of the cranium and 
mandible (76,77). The role of the extracellular matrix in palatal shelf elevation has been 
supported by some studies and is presently accepted as an important determinant of 
palatal shelf elevation (78,79). Those studies (77) suggested that a progressive 
accumulation of glycosaminoglycans, primarily hyaluronan in the palatal shelves, plays 
a role in their elevation (78,79). Hyaluran is a highly charged glycosaminoglycan that 
retains high amounts of water, forming hydrated gels leading to the expansion of the 
extracellular matrix. Other constituents of the palatal shelves including collagen fibers, 
vascularization, and the epithelial covering; the polarized alignment of the mesenchyme 
cells may also contribute to the intrinsic elevation force of the palatal shelves. Mutations 
of Pax9, Pitx1 or Osr2 can lead to failed palatal shelf elevation and CP defect (80-83). 
The cellular defect is associated with the CNC-derived palatal mesenchyme, suggesting 
the important functions of these transcription factors in regulating the fate of the CNC 
cells during palatogenesis. Early studies attributed a role to the neurotransmitters during 
palatal shelf elevation (77). At present, it is widely accepted that neurotransmitter γ-
aminobutiric acid (GABA) regulates not only neuronal activities but also cell migration, 
survival, proliferation and differentiation of neuronal and non-neuronal cells (84-86). 
Teratological studies in rodents showed that GABA or GABA agonists generate CP by 
inhibiting palatal shelf elevation, whereas GABA antagonists stimulate the process (87). 
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The implication of GABA in palate development was demonstrated by genetic studies of 
mice lacking the β3 subunit of the GABA receptor that developed CP without other 
craniofacial malformations (88). 
Failure of Palatal Shelves to Meet After Elevation 
Fusion of the opposing palatal shelves is an important step, taking place through 
a sequence of events that includes the removal of the flat peridermal cells, contact and 
adhesion of the opposing MEE, which creates the MES. The MES disintegrates and the 
mesenchymal confluence is achieved at the midline (9,10,22). Failure of shelf fusion is 
the most common type of CP defect documented in animal studies. Mutations in Msx1 
and Lhx8 and conditional inactivation of TGFbr2 in CNC cells or Shh in the epithelium 
all result in retarded palatal shelf development (12,68).  
Persistence of Middle Edge Epithelium 
Adhesion of the opposing MEE is an important event in both human and mouse 
embryos (8,15,22,32,89). E-cadherin is expressed in the epithelia covering the 
frontonasal and medial nasal processes as well as during the different stages of palate 
development, including the epithelial islands, remnants of the MES (90-92). Mutations 
of CDH1/E cadherin, which deletes the extracellular cadherin repeat domains required 
for cell-cell adhesion, have recently been associated with CLP in families with 
hereditary diffuse cancer (93). E-cadherins are known to form dimers, indicating that the 
mutant proteins may have trans-dominant negative effects over the normal proteins (93).  
Extensive efforts have been made to elucidate the role of TGFβ3 during palatal 
fusion (94-97). Adhesion of the MEE upon palatal shelf contact is a necessary step for 
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fusion. TGFβ3 is expressed in the MEE before and during fusion, and mediates MEE 
adhesion of the opposing palatal shelves through filopodia. E-cadherin is required for 
fusion, whereas filopodia seem to be crucial for proper alignment and guidance of cell 
sheets that are fated to fuse, but not for fusion itself (98). TGFβ3 is implicated in 
controlling the remodeling of the extracellular matrix through regulation of the 
expression of the matrix metaloproteinases (Mmps) Mmp13, Mmp2 and the tissue 
inhibitor of metalloproteinase-2 (Timp) (99). TGFβ3 signaling functions in the MEE by 
mediating the epithelial-masenchymal interactions leading to tissue changes that regulate 
palatal fusion. For example, EMT of the MES has been proposed as the major 
mechanism underlying the disappearance of the MES to generate mesenchyme 
continuity, thus preventing palatal clefts (22). The establishment of the concept of EMT 
as the prevailing mechanism of MES disappearance leading to studies attributing roles to 
different molecules, including TGFβ3, Lef1, Smad, RhoA, phosphatidylinositol 3-kinase 
(PI-3 kinase), Mmps, Twist and Snail (9,21,100). In TGFβ3 or Egfr mutant mice, there 
is an alteration of the fate of MEE cells (101,102). In TGFβ3 null mutant mice, MEE 
cells fail to undergo apoptosis and remain along the midline, preventing normal fusion.  
 
SUMO Modification of Signaling Pathways in Palatogenesis 
The molecular understanding of NS (nonsyndromic) CLP is further complicated 
when one considers that large differences in penetrance often occur when the same 
mutations are placed on different strains, indicating a potential role for both genetic and 
or environmental modifiers in the pathogenesis of CLP. Several lines of evidence point 
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to the involvement of the small ubiquitin-like modifier (SUMO) posttranslational 
modification machinery (12,103). SUMO proteins are a family of small proteins that are 
covalently attached to and detached from other proteins in cells to modify their function. 
SUMOylation is a post-translational modification involved in various cellular processes, 
such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein 
stability, response to stress, and progression through the cell cycle. A surprisingly 
specific role in orofacial development has been revealed for protein modification by the 
SUMO, which hints at a possible interaction with environmental factors. Small 
ubiquitin-related modifiers belong to the ubiquitin-related protein family, and SUMO 
proteins are ubiquitously expressed throughout the eukaryotic kindom (12,104). SUMO1 
shows strong expression in the edge epithelial of the secondary palate (105). A 
translocation breakpoint interrupting SUMO1 was found in a patient with CLP (12,105). 
The causative nature of the translocation defect has been confirmed in SUMO1-deficient 
mice having a distinct CP phenotype (12,105). Furthermore, it was recently shown that 
mutations in TBX22 have a profound effect on its ability to be sumoylated, which is at 
least partially responsible for its loss of function (12,106). Other SUMO targets include 
Smad4, Msx1, p63, Pax9, Eya1 and FGF signaling (12,103). It seems likely that some of 
these factors may manifest through the disturbance of the SUMO pathway. Destabilizing 
the normal balance of expression and activity for genes such as TBX22, Msx1, SATB2, 
and p63 during early pregnancy is likely to provide a high-risk environment for the 
occurrence of CLP (12). Elucidating the relationship among environmental factors, the 
SUMO pathway, and the networks of craniofacial genes influenced by this 
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posttranscriptional modification may be crucial to the understanding of the idiopathic 
forms of orofacial clefts (12).  
 
A-P Gradient of Molecular Signaling in Palatal Development 
Multiple genes are critical for the development of the anterior region of the 
palate. Msx1, Bmp4, Bmp2, Fgf10, and Shox2 have restricted expression patterns in the 
anterior region of the palate (12,68,107). In addition to the differential gene expression 
patterns along the A-P axis of the developing palate, there is also mesenchymal 
heterogeneity between the medial and lateral regions of the palatal shelf. The odd-
skipped related genes Osr1 and Osr2 are expressed in a medial-lateral gradient in the 
palatal shelf. The mutation of the Osr2 gene results in the compromised development of 
the medial aspect of the palatal shelf and retards palatal shelf elevation (12,83,108). The 
expression of Fgfr2 is focused on the medial aspect of the developing palatal shelf, 
suggesting a possible functional significance in regulating its development and elevation.  
An important discovery has been the confirmation of genetic heterogeneity along 
the anterior-posterior and medial-lateral axes of the developing palate (36). This 
heterogeneity may provide a differential regulatory mechanism for the fusion of the 
anterior vs. posterior region of the palate. MEE cells undergo apoptosis at different times 
during palatal fusion. It has been shown that the apoptosis of MEE cells is triggered by 
palatal shelf contact in the anterior region, whereas it is initiated before any contact 
between the opposing shelves in the posterior region (26). This difference may be the 
result of dissimilar molecular signals in the palatal mesenchyme along the 
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anteroposterior axis that instruct different fates to the palatal epithelium (12,109). Recent 
studies have demonstrated that constant and reciprocal interactions between the palatal 
epithelium and the CNC-derived mesenchyme are responsible for setting up this genetic 
heterogeneity along the AP axis and are crucial for normal palatal development and 
fusion (13,68,110). The specific gene expression patterns in the posterior region of the 
palatal mesenchyme are less understood. Fgfr2 is expressed in the epithelium, and the 
CNC-derived mesenchyme is found in the middle and posterior palate. FGF8 signaling 
selectively induces the expression of Pax9 in the posterior region of the palatal 
mesenchyme. The loss of Pax9 results in a palatal shelf development defect and a CP 
(36,81). 
 
Types of Cleft Palate  
CP or CLP may involve both the primary or secondary palate (frequently both 
complete clefts). Those involving the primary palate are associated with clefts of the lip. 
Palatal clefts may also be unilateral or bilateral. Isolated clefts of the secondary palate 
(incomplete clefts) occur in the absence of defects in either the lip or the alveolar 
process. Because palatal fusion occurs in an anterior to posterior direction, clefts of the 
secondary palate may involve only the soft palate or both the soft and hard palates 
together (111). 
Clinically, clefting in the secondary palate extends anteriorly from the uvula to 
varying degrees, often involving the hard palate (112). In complete forms, the cleft can 
affect the entire secondary palate, reaching the incisive foramen, leaving the 
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nasopharynx in direct communication with the oral cavity. Thus, the vomer can be seen 
as a midline structure extending from the base of the skull. While complete and 
incomplete clefts of the palate may be readily apparent on physical exam, other forms 
may also exist with regard to feeding, speech development and ear infections (113). 
 
Epidemiology 
CLP affects with variability across geographic origin, racial and ethnic groups, as 
well as environmental exposures and socio economic status. In general, Asian and 
Amerindian populations have the highest reported birth prevalence rates, often as high as 
1/500, European-derived populations have intermediate prevalence rates at about 1/1000, 
and African-derived populations have the lowest prevalence rates at about 1/2500 
(114,115). These observations suggest the relative contribution of individual 
susceptibility genes may vary across different populations. The frequency of CLP also 
differs by sex and laterality: there is a 2:1 male to female ratio for clefts involving the lip 
and approximately a 1:2 male to female ratio for clefts of the palate only; and there is a 
2:1 ratio of left to right sided clefts among unilateral CL cases (114).  
 
Environmental Factors and Gene Interactions 
The etiology of CL with or without palate (CLP) is theorized to be a combination 
of factors associated with genes and environment (65,116). The advent of gene targeting 
technology and basic conventional techniques using animal models has led to the 
identification of genes associated with known and unknown etiologic factors. The 
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characterization of the genomic sequences will greatly impact the regulation of gene 
networks and pinpoint any variations in the different stages of craniofacial 
morphogenesis. There is emphasis placed on the different genes associated with the 
classifications of CLP into syndromic (Table 1) and nonsyndromic genes (Table 2). Each 
classification plays a significant role in the understanding of the molecular and genetic 
mechanisms affecting these types of craniofacial defects (66,67,117). In addition to 
known genes, there is strong evidence that several environmental factors (e.g., alcohol 
consumption, tobacco, and anti-convulsants) increase the risk of CLP (118,119). In 
contrast, several studies have shown that folic acid may have a protective effect on CLP 
and neural tube defects (120-124). Data from the National Birth Defect Prevention 
Network have indicated a decrease in neural tube defects from 5/10,000 to less than 
2/10,000 after the fortification of the food supply with folic acid, indicating that this 
vitamin and the proteins that facilitate the uptake and metabolism of folic acid may be 
candidate genes in craniofacial development (122,125-128). 
  Maternal smoking has been associated repeatedly with increased risk of CLP 
analysis supports an overall odds ratio (OR) for having CLP of ~1.3 among offspring of 
mothers who smoke (16). Increased risk from exposure to maternal smoking during the 
peri-conceptual period raises the possibility that genes in certain metabolic pathways can 
play a role in the development of CLP. Markers in GSTT1 (glutathione S-transferase 
theta) or NOS3 (nitric oxide synthase 3) genes appear to influence risk of CLP in the 
presence of maternal smoking (129). The GSTT1 markers are gene deletion variants, 
which suggest deficiencies in detoxification pathways may underlie some of this 
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susceptibility. Smoking has also been associated with a joint risk with variants in the 
IRF6 gene and the same study reported interactions between multivitamins and IRF6 
variants. Some specific teratogen, for example valproic acid have evidence of 
association with CP. Exposure to maternal alcohol consumption has also been suggested 
as a risk factor, but the evidence has been more inconsistent. Studies also suggest that 
drinking patterns (high doses of alcohol in short periods of time) increase risk (130). 
This is supported by variation in the ADH1C alcohol dehydrogenase gene. Nutritional 
factors, such as folate deficiency, have also been suggested to influence risk of CLP, 
based on both observational studies and trials using folate supplementation to prevent 
recurrences of CLP in families. However, the studies of vitamin supplementation with 
folate remain controversial, and recent studies of levels of folate receptor antibodies did 
not find an association with CLP. Furthermore, food fortification programs using folic 
acid have shown detectable decreases in the rates of clefting in some but not all studies. 
In the future, other nutrient and micronutrient studies will need to be studies in otder to 
find evidence of effects. For example, there is data to support roles for zinc deficiency in 
risk of oral clefts in populations in which zinc status is highly compromised, for 
cholesterol deficiency in facial clefting, as well for as multivitamins in general in cleft 
prevention. 
Recent studies found that mothers who ate liver periconceptionally were at a 
decreased risk of having a child with a CLP compared to mothers who did not (131). A 
3-oz portion of pork, beef, or veal liver contains more than 600% of the recommended 
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dietary allowance for vitamins A and B12 and more than 50% for folate, zinc, and 
vitamin B6 (US Department of Agriculture, 2013).  
Besides nutrients and toxins other environmental exposures have been, and 
should continue to be, assessed for possible roles in clefting. These exposures include 




Researchers hoping to study the genetics of CLP were haunted by reviews stating 
that "babies born with clefts can be treated in their first year of life and understanding 
the genetics contribution to clefts will not change the outcome of these cases” (133). 
Recent work has suggested that this was an underestimation of the consequences of 
being born with facial clefts. Individuals born with clefts have a shorter lifespan, with 
increased risk for all major causes of death, when compared with individuals born 
without clefts. Contributing to these higher mortality rates are probably psychiatric 
disorders and cancer (134). Facial clefts increase the risk of hospitalization for 
psychiatric diseases in adults. Also, an increased occurrence of breast and brain cancer 
among adult females born with oral clefts, and an increased occurrence of primary lung 
cancer among adult males born with oral clefts have been reported (131). 
Psychiatric disorders can be interpreted under the assumption that the 
development of the brain and that of the face are intimately related in both normal and 
pathologic conditions, and suggest that abnormal brain development might accompany 
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an abnormality in facial development. Animal models have shown that forebrain 
development and facial development are linked. Molecular signaling in the forebrain 
regulates the establishment of a signaling center in the face, and thus controls its 
subsequent morphogenesis (135). The molecular dialogue that exists between these 
tissues is essential for patterned outgrowth of the middle and upper face. It appears that 
defects in signaling within the forebrain can lead to a wide variety of craniofacial 
malformations, including CLP (135).  
 
Ossification of the Palate  
Palatal fusion signals the start of the ossification process in the anterior two-
thirds of the palate to form the hard palatal tissues. This process entails the successful 
fusion of the three embryonic structures, namely, the lateral edges of the primary palate 
with the two anterior edges of the secondary palate. This process requires the 
synchronization of shelf movements together with the growth and withdrawal of the 
tongue and the growth of the mandible and head (136). Any form of disruption during 
the formative stages results in a pathological cleft.  
A wide range of studies on craniofacial skeletal maturation has shown that the 
fusion of the palatal shelves along their length to form the mid-palatal (MP) suture 
occurs during the ossification of the maxillae and palatine bones before the mandibular 
condyle develops (36,137,138). Ossification is observed where mesenchymal cells 
condense, the surrounding tissue vascularizes and the cells differentiate into osteoblasts. 
There is a number of growth and differentiation factors involved in this process, such as 
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Bmps, core binding proteins (Cbf), Fgfs, and hh proteins that interact with various 
signaling pathways to regulate the patterning of the undifferentiated mesenchyme. Bmp-
6 and the transcription factor Gli1 are also expressed during intramembranous bone 
formation (139-141). As in the craniofacial sutures, the mid-palatal (MP) and trans-
palatal (TP) suture osteoblasts express TGFβ 1,2 and 3, while the suture cells express 
primarily TGFβ3 (142,143).  
 It has been established that cranial sutures are the growth sites for the 
neurocranium and that the dura mater provides the signaling molecules to regulate suture 
patency (144). The MP and TP sutures have different morphology, so they are not in 
contact with the dura mater. There is an hypothesis, that these facial sutures are growth 
centers (142,143) and that the nasal capsular cartilage produces signaling molecules to 
regulate the fusion of the MP and TP sutures (Fig. 1-3) (143). The nasal cartilage 
maintained the TP sutures as growth sites in experiments on rat palatal organ cultures 
(E20) with or without nasal cartilage. Thus, it was  theorized that the nasal cartilage may 
regulate mid-facial growth (12,143).  
Animal models have been developed to understand the etiology and pathogenesis 
of orofacial clefts and the mechanisms of normal palatal ossification. The application of 
cyclic forces is an effective mechanical stimulus for the regulation of osteogenesis and 
osteoclastogenesis in the sutural growth of neonatal rats (145). The process of tissue 
response and regeneration in the palato-maxillary suture under tensile forces was 
examined histologically and fluorescently. A cyst-like zone appeared in the conjuncture 
of the bony front and the sutural connective tissue at the early stage of sutural expansion 
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with increased proliferating osteoblasts and fibroblasts. New bone was deposited along 
the nasal septum and the front of the cyst until the new bone front formed and the suture 
restored its original morphology (146). 
The approach of utilizing MP suture expansion in mice has provided new 
insights into mechanical stress modulation as an important factor for the skeletal 
remodeling of bones and cartilage. The expansive force across the MP suture promotes 
both bone resorption through the activation of osteoclasts and bone formation through 
the increased proliferation and differentiation of the periosteal cells (147). Similarly, the 
use of orthodontic wire expansion in growing rats showed that secondary cartilage could 
undergo chondrogenic and osteogenic differentiation in the maxillary arch. Interestingly, 
these induced changes were attributed to the alteration of the differentiation pathway of 
progenitor cells from chondroblastic to osteoblastic, in which many sutures temporarily 
form secondary cartilage during early development. Histological observations at days 7, 
10, and 14 indicated that intramembranous bone formation, which is partially recognized 
as mature bone (148), occurred at the boundary between the precartilaginous and 
cartilaginous cell layers where the calcified matrix was positive for osteocalcin antibody. 
The cellular events taking place at the MP suture cartilage in rat models as a result of 
expansion force have been observed as endochondral bone formation at the boundary 
between the maxillary bone and cartilage. Whereas, intramembranous osteogenesis has 
appeared at the internal side of the cartilaginous layer (149). To stimulate new bone 
formation in defective tissues, rat organ cultures with distracted palatal sutures were 
treated with Bmp-7 and Nell-1 for 8 days in vitro. The presence of Nell-1 increased 
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chondrocyte hypertrophy and endochondral bone formation while Bmp-7 enhanced both 
chondrocyte proliferation and differentiation in the distracted palates of 4-week-old male 
rats. This study indicates that Nell-1 was involved in the rapid osteoblast differentiation 
in palate sutures (150). In another study, the application of TGF-β1 during the early 
stages of rat MP expansion induced rapid bone formation at the suture site (151). 
Many research investigations have also explored the importance of distraction 
osteogenesis (DO) since its introduction by Ilizarov in the 1950s. This treatment is a 
special form of bone healing that has applied both basic and clinical research models in 
which well-controlled distraction stresses and subsequent tensile strains within callus 
tissues produce new bone formation at an unusual rate (152). The application of DO to 
craniofacial disorders is being actively investigated for purposes such as midfacial 
advancement, hard palate suture expansion, elongation, and alveolar cleft closure (153-
157). However, a review of studies revealed that no single investigation concerning the 
use of DO has been done to close a hard palate cleft in humans due to the thin layer of 
hard palatine bone. One possible method to supplement existing treatment modes is to 
induce new bone formation and soft tissue migration over the cleft before definitive 
surgery. The technique of DO in which bone is lengthened gradually under tension after 
an osteotomy was utilized in dogs. Through histological analysis of the specimens, the 
results of this trial confirmed that distraction promoted bone healing at the cellular level. 
The appearance of osteoclasts and resorption lacunae signaled the initiation of the 
remodeling process. With time, an increased area of bone surface was covered with 
osteoid. There was evidence of numerous bone-forming osteoblasts interfacing with the 
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surface of nonmineralized bone matrix. The bone surface was extensively double-labeled 
with bone fluorochromes, indicating a high turnover of bone during the healing process. 
By 10-12 weeks, the osteoid formed was almost completely mineralized, as 
demonstrated by the bone occupying the surgically created cleft (157).  
 
Oral and Palatal Musculature and Related Deformities 
Overt CLP encompasses a broad spectrum of defects, ranging from so-called 
microform clefts; thus, unilateral or bilateral clefts of the lip and palate are completed. 
The orbicularis oris (OO) muscle consists of numerous differently oriented strata of 
muscular fibers that surround the orifice of the mouth. At approximately 7 weeks post-
conception (p.c.) in humans, the two maxillary prominences fuse with the medial nasal 
prominence; however, lip fusion is not complete until the epithelial seam disappears 
through EMT and/or apoptosis (136) (Fig. 1-2A-C). By 8 weeks p.c., a dense, 
continuous band of mesenchymal cells corresponding to the future OO muscle can be 
seen, with discernable OO muscle fibers present by 12 weeks. The complete OO muscle 
architecture forms by 16 weeks. Any delay in fusion may result in subepithelial OO 
defects, such as the altered migration of the mesenchymal cells. Subepithelial (non-
visible) defects of the orbicularis oris muscle represent the mildest form of CL, and such 
defects are part of the phenotypic spectrum of CLP. This defect usually is visualized as a 
ridge of tissue, resembling a scar on the upper lip along the philtrum (158).  
Histological studies have demonstrated that such defects spread to the muscle 
fibers of the superior OO muscle. A method using high-resolution ultrasonography was 
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developed to visualize the OO muscle non-invasively (159). Significant differences in 
the defects of the OO are found between in the first-degree relatives of CLP individuals 
and controls. The OO muscle defect detected by ultrasound is consistent with the 
histological examination of cadavers (159). Interestingly, the Bmp4 knockout mouse 
model shows bilateral CL at E14.5, although this condition occurs at a rate of 22% after 
birth (160), suggesting the initial CL is rescued or healed in utero, leaving only the 
subepithelial OO defect. Potential mutations in BMP4 were found in 2 individuals with 
OO defects and none in the controls (161). The strong evidence that OO discontinuities 
are indeed part of the phenotypic spectrum of CLP provides an important clue for the 
clinical recurrence risk estimation for families with members affected with CLP.  
The mildest form of CP is termed a "submucosal cleft palate", which is described 
as a bifid uvula, palatal muscle diastasis, and a notch in the posterior surface of the hard 
palate (162). Defects in the nasopharyngeal anatomy and/or physiology may lead to 
velopharyngeal incompetence (VPI). Although most VPI is caused by CP, the population 
prevalence of VPI due to other causes is estimated to be approximately 2.5% (163). In 
such cases, VPI may be caused by submucosal muscular defects of the levator palatine 
or musculus uvulae. Most of the soft palate muscles are derived from myotome cells, 
which first invade pharyngeal arch 4 and then migrate to the palate, carrying their 
innervations from the vagus nerve. One muscle (tensor veli palatini) is derived from 
myotome cells that first invade arch 1 and are innervated by the trigeminal nerve (164). 
In the mouse, the tensor veli palatine, levator veli palatine, medial pterygoid, and lateral 
pterygoid muscles are identified as myogenic fields as early as gestational day 15. The 
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palatoglossus, palatopharyngeus, and musculus uvula. However, are not clearly visible 
(165). In principle, the presence of these anatomical features in unaffected individuals 
may signify an elevated risk for producing clefts in offspring (166). 
 
Palate Repair 
Today, surgical repair of CL is performed around 2–3 months of age, with CP 
closure performed at 6–12 months (167). The earliest written account of a cleft surgery 
is from ancient China; the annals of the Chin dynasty from 390 AD recount the repair of 
CL in an 18-year-old man. Some of the features of the surgery (cutting and stitching the 
cleft edges) are essentially the same today, although various refinements now give more 
functional and aesthetic results. Surgical treatment of CP was first described in 1817 and 
was followed by many years of refinement of surgical techniques (167).  
The first report of a CP repair is attributed to LeMonnier, who incised the cleft 
edges and placed sutures leading to suppuration and then healing across the defect 
(38,111). Von Langenbeck in 1931 introduced the use of mucoperiosteal flaps to close 
clefts involving the hard palate (38). The most widely used techniques include Von 
Langenbeck’s, the Vaeu-Wardill- Kilner and the two-flap repair described by Bardach 
(38). While many modifications of each exist, the main principles across all CP repairs 
include tension-free closure of the oral and nasal layers, dissection of muscles from the 
posterior edge of the hard palate and construction of a horizontally oriented palatal sling 
to restore normal velar function (38). 
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Repair of the CP begins with an incision along the cleft margin at the junction 
between oral and nasal mucosa. The incision is carried anteriorly along the gingiva, 
allowing elevation of mucoperiosteal flaps off the hard palate (38). The tendon of the 
tensor veli palatini can also be divided medial to the hamulus to facilitate medialization 
of the levator muscle. The nasal mucoperiosteum is then widely mobilized from the 
undersurface of the hard palate. Posteriorly, an intravelar veloplasty is typically 
performed, with separation of the oral, muscle and nasal linings and release of the 
muscles from their abnormal attachment to the posterior edge of the bony palate (38). 
Closure of the defect is performed in three layers (nasal mucosa, velar muscle and oral 
mucosa), with horizontal reorientation of the levator veli palatini establishing proper 
orientation of the sling. In the region of the hard palate, a two-layer repair is performed, 
with the nasal layer sometimes requiring a vomerine flap (38,111). 
In patients with either clefting of the soft palate or a submucous cleft, a Furlow 
palatoplasty can also be performed. Double opposing z-plasties are fashioned on the 
velum, with release of the levator muscle from the posterior edge of the hard palate. 
Transposition of the flaps yields retropositioning of the muscle to a more medial-lateral 
position (38,168). With this technique, simultaneous palatal lengthening and 
reconstruction of the levator sling is established along with additional narrowing of the 
nasophayngeal aperture (38,169). Velopharyngeal competence allowing development of 
normal speech is one of the most critical outcomes in cleft surgery, and the Furlow 
technique has been associated with some of the lowest rates of persistent velopharyngeal 
insufficiency following primary repair (38,168,170). 
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While techniques for CP repair have become well established, postoperative 
development of oronasal fistulas still remains a significant problem. Reports have noted 
an incidence ranging from 11% to 23%, with the most likely site being the junction of 
the hard and soft palates (38,171). Several retrospective studies have identified the 
extent of cleft to be a significant factor, as patients with bilateral clefts were found to 
have a 2- to 3-fold higher incidence of postoperative fistula development compared with 
unilateral clefts (172). Operator experience has also been shown to play a role (172). 
Recent studies have evaluated the utility of the buccal fat pad as adjunctive tissue for use 
in both primary palatal cleft repair and treatment of postoperative fistulas. Used in a 
pedicled fashion with overlying mucosa, the buccal fat pad has been shown to 
successfully treated wide oroantral and oronasal clefts (38,173). More recently, buccal 
fat has also been employed to cover laterally exposed bone adjacent to gingival mucosa 
following medialization of the mucoperiosteal flaps (174,175). As this was found to re-
epithelialize within 2 weeks, use of the buccal fat pad may result in an eventual 
reduction of palatal scarring, which may limit subsequent growth restriction of the 
maxilla (38). 
Surgical repair of CP is the clinical standard of care. However, recent 
investigations showed the role of GSK-3 in the process. CP resulting from loss of GSK-
3β could be rescued by protein stabilization during a specific window in embryogenesis 
in the mouse model. A mutant mouse carrying alleles for GSK-3 was injected with 
rapamycin to inducibly stabilize GSK-3β during various 2-d windows in embryogenesis 
within the timeline of palate development. This transgenic mouse was engineered to 
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carry alleles for GSK-3β such that without drug addition the unstable FRB* tag would 
necessarily cause protein degradation, and the mouse would exhibit a null mutation 
phenotype. Subsequent histologic analysis revealed that without rapamycin, no GSK- 
β3F/F embryos were able to rescue the CP; however, with rapamycin injection of the 
pregnant dam between E13.5 and E15.0, the majority of conditional GSKβ3F/F mutant 
animals could be partially or completely rescued from their CP in utero. Rescue was not 
seen in other injection windows during palatogenesis, suggesting a critical role for GSK-
3β function in normal palatogenesis between E13.5 and E15.0 in the mouse model 
(176,177). 
GSK-3β has been implicated as a key regulator of a wide variety of 
developmentally important molecular pathways including Wnt, nuclear factor of 
activated T-cells (NFAT), Hedgehog, and insulin signaling. These signaling pathways 
are essential components of many biologic responses and associated diseases, including 
embryonic development and cell fate determination, diabetes, neurodevelopment and 
neurodegeneration, psychiatric disorders, cell cycle regulation and cancer, 
hematopoiesis, and immunity. GSK-3β has not previously been implicated in the 
development of the mammalian palate. However, because it is positioned at the “node” 
of so many significant developmental pathways, analysis of GSK-3β function during 
palatogenesis will likely provide important insight into this common birth defect. 
Because of the “promiscuous” nature of GSK-3β, it has become a potentially important 
therapeutic target. Many potent and selective inhibitors of GSK-3 function are being 
developed by the pharmaceutical industry (178). 
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Although GSK-3β mutations have not been documented to be a cause of human 
orofacial clefting, recent findings suggest it is clinically relevant because of the potential 
to devise methods for improved treatments, including in utero rescue, for human 
orofacial clefting. Investigations of GSK-3β role in palatogenesis promise future clinical 
applicability, because it has the potential to reveal signaling pathways underlying cleft 
formation and lay the groundwork for potentially improved treatments using small 
molecules. 
 
Palatal Tissue Engineering  
The management of CP in patients has improved significantly over 20 years. The 
use of autogenous grafted material is now the standard of care, but tissue engineering is 
an attractive alternative that could greatly reduce the morbidity of surgery and 
potentially enhance the healing process (38). Regarding mucosal repair, cultured 
epithelial grafts, dermal substitutes and a combination of the two, called mucosa 
equivalents, are commonly used to provide extra tissue and aide in wound healing after 
CP repair (38). Cultured epithelial grafts can provide coverage for large areas while 
being derived from only a small biopsy, but they are prone to infection and fail to reduce 
scarring or contraction in full-thickness wounds due to absence of a dermal component 
(179). Such grafts can be either allogenic or autologous. Allogenic grafts have the 
advantage of being readily available but have a low take rate and are generally only used 
for temporary coverage, while autologous grafts take require extra time to culture but 
have a higher take rate (38). Dermal substitutes made from polymers, purified collagen 
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or de-epidermized dermis (DED or AlloDerm) provide additional physical support that is 
often lacking in epithelial grafts. However, some require a secondary procedure to apply 
a split thickness skin graft or cultured epithelia. In recent years, repair of palatal fistulas 
have begun to employ acellularized dermal matrix (AlloDerm) with promising results. 
Using AlloDerm as an interpositional layer between nasal and oral mucoperiosteum has 
significantly reduced fistula recurrence rates (38,180,181). Recent studies have also 
demonstrated the utility of AlloDerm as an adjunctive measure in the primary repair of 
wide clefts (38).  
Cultured mucosa equivalents provide an epithelial and dermal substitute in a one-
step process, which seem to be the optimal replacement for mucosa, since this provides 
material for repair with properties closest to the original tissue. In CP repair, one of the 
major challenges lies in reconstructing the bony hard palatal and alveolar defects. 
Surgical repair with autogenous bone grafts is the current standard of care. Bone is most 
commonly harvested from the iliac crest but can be taken from the rib, tibia, calvarium 
or mandibular symphysis (38). This often requires multiple operations and extensive 
healing time and is associated with high donor site morbidity, including postoperative 
pain, altered sensation, scarring and infection. In addition, bone graft harvest ultimately 
yields a very limited quantity of bone for reconstruction (38,175). 
This bone often does not fully integrate into the host site and can undergo some 
resorption. Bony repair needs to be very strong to support tooth eruption and to 
withstand physical stress from muscles of mastication. There are also allogeneic and 
synthetic materials available for grafting, and while these solve the problem of donor site 
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morbidity, there is still the risk of infection, elicitation of an immune response and 
problems with structural integrity and contour (38). The use of tissue engineering could 
avoid many disadvantages of autogenous grafting, such as donor site morbidity, and 
could potentially decrease the number of surgeries needed while providing improved 
outcomes.  
 
Craniofacial Engineering Using Stem Cells  
Mesenchymal Stem Cells (MSCs) 
The identification of pluripotent MSCs in the bone marrow stroma over 25 years 
ago has led to a variety of research avenues. Capable of differentiating to multiple 
mesodermal lineages, including bone and cartilage, MSCs have become a standard in the 
field of adult stem cell biology and in regenerative medicine (182,183). It is only natural 
that these stem cells would be used in the repair of significant bony defects caused by 
trauma, surgery, or disease. Consistent with this, multiple studies have reported the 
formation of bone tissue both in vitro and in vivo upon the combination of MSCs and 3D 
scaffold supports. In vitro, a wide spectrum of scaffolds are being combined with MSCs, 
including chitosan or gelatin, electrospun collagen nanofibers, honeycomb collagen 
scaffolds, and titanium meshes (184). In animals, the scaffolds and model systems used 
have varied from Hydroxiapatita (HA) ceramics or hydroxyapatite and tricalcium 
phosphates (HA/TCP) constructs for the healing of small bone defects in rodents or 
larger defects in dogs, rabbits, or sheep to complicated biosynthetic composites to silk-
based biomaterials in the healing of segmental femoral defects in nude mice(138). Each 
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of these studies report encouraging results and espouse the use of bone marrow MSCs in 
the repair of bony defects (2,185). 
Adipose-derived Stem Cells (ASC) 
Historically, the adipose compartment has been considered primarily a metabolic 
reservoir of storing, and releasing high-energy substrates. Today, the adipose 
compartment may be a site for an abundant population of stem cells, ASC or adipose-
derived stem cells (2). Like the bone marrow, adipose tissue contains an extensive 
cellular stroma comprised of fibroblastic-like cells termed by Rodbell in 1964 as the 
stromo-vascular fraction or SVF. Further work by Hauner expanded this knowledge and 
postulated that the preadipocytes within the SVF represented a progenitor population, 
though apparently limited to the adipocytic lineage (186). However, in 2001, Zuk et al. 
showed that the SVF fraction isolated from human lipoaspirates in fact contained cells 
with multilineage potential and termed these cells pressed lipoaspirate cells (2). Now 
renamed ASCs, these cells undergo adipogenesis, osteogenesis, chondrogenesis, and 
myogenesis in vitro, suggesting that the SVF fraction of adipose tissue may, in fact, be 
comprised not just of lineage limited preadipocytes but of multipotent stem cells. ASCs 
have also become a hot topic in the world of tissue engineering. Numerous studies have 
begun to explore the osteogenic potential of ASCs in vivo through their combination 
with a wide variety of scaffolding materials. Groups led by Lee and Hicok were the first 
to show that implantation of human ASCs loaded onto polyglycolic scaffolds could 
result in the formation of an osteoid material (2,138,187,188). 
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To improve their ability to form bone, many of these studies treat ASCs with the 
osteogenic growth factor BMP2. Both Peterson and Dragoo were the first to describe the 
engineering of well-formed bone by ASCs in rodents with the help of bone morphogenic 
protein 2 (BMP2) and several MSC studies have shown that this osteogenic factor can be 
used in concert with these stem cells also. Many of these studies claim that increased 
bone formation can be attributed to the presence of BMP2- treated ASCs. However, 
work by Leboy has suggested that BMP2 may not promote osteogenic differentiation of 
human MSCs. Similarly, in patients receiving recombinant BMP2 treatment, the 
regenerative response is several times lower than that previously measured in animal 
studies, suggesting that the response of human cells to BMP2 may not be directly 
comparable to that observed by animal cells. Although several studies have begun to 
combine BMP2 and ASCs, surprisingly, to date, no in-depth in vitro studies have been 
performed to confirm if BMP2 can actually promote ASC osteogenesis (2). 
Scaffolds  
Efficient use of 3D scaffold systems in bone repair is dependent upon their bond-
bonding or bioactive ability. Alhough scaffolds such as Poly lactic glycolic acid (PLGA) 
or Poly lactic acid PLA composites provide the reconstructive surgeon with a 
biodegradable platform for stem cell adhesion and differentiation, their bioactivity can 
be limited. However, studies have suggested that their bioactivity can be strengthened 
through the formation of a layer of hydroxyapatite (HA) at the bone-implant interface 
(2). Several HA materials for use in bone differentiation have been developed within the 
last 20 years and are thought to possess superior in vivo bioactivity. However, much 
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excitement has been generated regarding the osteoinductive capacities of biomimetic 
apatite coatings. Typically created through the immersion of 3D scaffolds in ionic 
solutions with compositions similar to blood plasma called Simulated Body Fluids 
biomimetic apatites are composed of plate-like crystals of calcium phosphate capable of 
coating the entire 3D scaffold architecture (189,190). An improvement on biomimetic 
apatites presented by Wu and colleagues through their development of accelerated 
biomimetic approaches, which have dramatically shorten the time required for coating 
from approximately 2 weeks to 2 days (191). Such convenience may make the 
accelerated biomimetic apatite more attractive for in vivo applications such as bone 
healing. In support of this, accelerated apatite coatings have been shown by Wu and his 
group to promote bone in-growth and differentiation of preosteoblasts and bone marrow 
stem cells and to enhance direct bone to bone contact. Recently, accelerated apatites 
have also been shown to promote the osteogenic capacity of ASCs. In a paper by Cowan 
et al., murine ASCs seeded onto accelerated apatite coated PLGA scaffolds healed 
critical-sized cranial defects without the need for exogenous stimulation such as BMP2 
treatment (192). Although the ASCs used were murine and no further studies using 
human ASCs have been reported, these results remain exciting because they show the 
reconstructive surgeon that methods other than conventional growth factor stimulation 
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Conclusion 
CLP is caused by many factors, including both genes and environment. Gene 
targeting technology and basic conventional techniques using animal models led to the 
identification of genes associated with known and unknown etiologic factors. However, 
it should be noted that there are other cases where the human gene deficiency was 
identified first and replicated in an animal model. It is also clear from this extensive list 
of possible contributing genes that the molecular and cellular interactions associated 
with CLP are not all understood. Tissue engineering approaches also remain an exciting 
and potentially profitable direction of investigation as the field of regenerative medicine 
advances. 
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CHAPTER II  
EPHRIN REGULATION OF PALATE DEVELOPMENT* 
Synopsis 
Studies of palate development are motivated by the incidence of cleft palate. 
Although, mechanistic studies of palate growth and fusion have focused on growth 
factors such as TGFβ3, recent studies have revealed that the ephrin family of membrane 
bound ligands and their receptors, the Ephs, play central roles in palatal morphogenesis, 
growth, and fusion. In this chapter, the recent findings on the functions of ephrins in 
palatal development will be discussed. 
Introduction  
Ephrin Involvement in Palatal Growth and Fusion 
The Eph family is the largest family of mammalian receptor tyrosine kinases. 
Ephs and their membrane-bound ephrin ligands are responsible for multiple adhesion, 
migration, and boundary forming events throughout development, particularly midline 
fusion events such as urorectal closure (193-195). Binding of ephrins to Ephs on 
opposing cells causes kinase activation in the Eph-bearing cells (forward signaling), 
*Reprinted with permission from “Ephrin Regulation of Palate Development” by M.
Douglas Benson and Maria J. Serrano, 2012, Frontiers of Physiology, v.3, 376, 1-5, 
Copyright 2012 by Benson and Serrano. 
*Reprinted with permission from “Ephrin reverse signaling controls palate fusion via a
PI3 kinase- dependent mechanism” by Symone San Miguel,Maria J. Serrano,Ashneet
2011, Developmental Dynamics, v  240, 357-64 Copyright 2011 John Wiley and 
Sons
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while binding of Ephs can activate intracellular signaling inside ephrin-bearing cells 
(reverse signaling). Ephrin-Bs are transmembrane proteins that have conserved 
intracellular signaling domains while ephrin-As are glycosylphosphatidyl-inositol (GPI)-
linked and use co-receptors to signal. Ephrin-As preferentially bind to the EphA subclass 
of receptors, while ephrin-Bs bind to EphBs, although there is physiologically relevant 
binding across classes, most notably between EphA4 and all three B ephrins. 
Over the years, a number of genetically modified Eph and ephrin alleles have 
been created in mice to both track expression of these molecules and to examine the 
roles of forward and reverse signaling in developmental processes. In addition to 
traditional gene knockouts, several LacZ knock-in alleles have been generated. In these, 
either the entire protein or just the cytoplasmic domain of the Eph or ephrin-B in 
question is replaced with a bacterial beta-galactosidase moiety that can be visualized in 
tissue by incubation with X-gal to produce a blue precipitate. The chimeric alleles are 
especially useful because they lack intracellular signaling ability while retaining activity 
as ligands from their extracellular domains. Thus, they can be used to separate forward 
and reverse ephrin signaling pathways. 
The first evidence that ephrins play a role in palate development came with the 
linkage ephrin-B1 mutations to craniofrontonasal syndrome in humans, of which CP is a 
prominent feature (196,197). At the same time, Davy, et al. reported that deletion of 
ephrin-B1 in cranial neural crest cells in mice caused craniofacial deformities, including 
CP (198). The fact that these defects resulted from cell-autonomous ephrin-B1 deletion 
suggested that ephrin-B1 reverse signaling is important for palate formation. Five years 
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later, Risley et al. reported that forward signaling through the combination of EphB2 and 
EphB3 is necessary for growth of palatal mesenchyme (49). These authors used EphB2 
LacZ/LacZ; EphB3-/- compound mutant mice to create forward signaling double knockout 
mice (EphB3 signaling is removed while EphB2 forward signaling is removed and 
reverse signaling is still intact). These mice had CP from stunted palatal shelf growth, 
while EphB2 and EphB3 single mutants alone did not. Shortly after the Risley study, 
Bush et al. found that forward signaling from ephrin-B1 in palate mesenchyme was 
required for mesenchymal proliferation through a mechanism requiring MAPK/ERK 
activation. Without ephrin-B1, mice displayed CP because the shelves failed to grow to 
midline (46). These data together suggest that Ephs B2 and B3 function as the receptors 
for ephrin-B1 in palate mesenchyme. The EphB2 kinase was recently shown to increase 
proliferation in intestinal cypts through stimulation of Cyclin-D1 levels downstream of 
Abl activation (199). 
When palatal shelves from EphB2 LacZ/LacZ; EphB3 -/- compound mutants were 
placed in contact with each other in culture, they adhered to form an MES and fused 
normally (49). This demonstrated that EphB2 and EphB3 forward signaling are not 
required for fusion, and that reverse signaling from EphB3 alone is not critical for 
fusion, although the extracellular domain of EphB2 was still able to act as a ligand for 
reverse signaling in these mice. 
In embryonic palate, the expression of Ephs and ephrins was examined using  
LacZ indicator mouse lines. A summary of these expression patterns in fusing palate 
combined with those for Ephs and ephrins in the published literature is presented in 
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(Figure 2-1). Ephrin-B2 and EphB2 were found to express specifically in the MES 
immediately prior to and during its degradation. This suggested that ephrin signaling 
contributes to palatal EMT and fusion.  
A group of researchers had reported a study in which 26% of mice homozygous 
for the ephrin-B2LacZ allele had CP (200). In these experiments only a minority of these 
embryos had CP, suggests that other Eph and ephrin family members contribute to 
reverse signaling at the midline and remain unaccounted for. This is not surprising, as 
Eph/ephrin mediated developmental processes are frequently under redundant control by 
multiple family members, including in palate, as noted above. Interestingly, the study by 
Dravis et al. also showed ephrin-B2 expression in the mesenchyme before its re-
localization to the MEE at the time of fusion, suggesting that ephrin-B2 plays a role in 
palatal shelf growth alongside ephrin-B. 
They also showed EphB3 expression in the MEE at fusion, implicating it in the 
fusion process. These data emphasize the likely involvement of multiple Eph and ephrin 
family members in both phases of palatal development. 
If ephrin-B1 is expressed in the palatal mesenchyme, and ephrin-B2 in the 
epithelium, how might these two molecules combine to mediate MES degradation and 
fusion? One possible answer may be found in recent studies on the role of ephrin 
signaling in cancer cell migration. (201). Astin et al., demostrated that prostate cancer 
cells are prodded along in their migration through fibroblasts by the activation of 
EphB3/EphB4 forward signaling in response to ephrin-B2 ligand from the surrounding 
fibroblasts (201). This forward signal activates Cdc42 within the cancer cells to 
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eliminate contact inhibition and increase their invasiveness. It may be that a similar 
mechanism is at work in palatal MEE cell migration through the ephrin-B1-expressing 
mesenchyme. Whereas reverse signaling in MEE cells initiated by contact with Ephs 
(acting as ligands in reverse signaling) on the opposing shelf MEE begins the process of 
EMT, mesenchymal ephrin-B1 (acting as ligand) activates forward signaling in the 
former epithelial cells to continue their migration and complete MES degradation. 
Ephrin-B1 may also provide a signal to the migrating former MEE cells that causes their 
eventual apoptosis, as B ephrin forward signaling is known to cause apoptosis in other 
systems (202). 
Ephrin Signaling in Palatal EMT and Fusion 
Ephrin reverse signaling was found in the chicken palate and it was sufficient to 
cause palatal fusion without the presence of TGFβ3, and that TGFβ3 cannot cause 
fusion without the ephrin signal. Yet there is clearly a question of signaling level. The 
fact that chicken palates cultured without TGFβ3 will not fuse unless exogenous 
EphB2/Fc is added, and that TGFβ3 knockout mouse palates do not normally fuse, 
indicates that the level of ephrin reverse signal naturally present in palatal tissue is not 
enough to overcome a lack of TGFβ signaling. The TGFβ3 and ephrin pathways must 
interact in one of two ways. The first possibility is that TGFβ3 activates expression of 
ephrins and/or Ephs in palate tissue to reach a threshold level required to activate fusion. 
In this model, ephrins are genetically and mechanistically downstream of TGFβ3. The 
second is that the two act in parallel, but intersect such that the TGFβ3-activated signals 
add to those elicited by ephrin activation to reach the level necessary to cause MES 
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degradation. The ephrin signal must still be preeminent; however, as elevated ephrin 
stimulation obviated the need for TGFβ3 in the palate fusion assay, while addition of 
exogenous TGFβ3 did not compensate for a lack of ephrin signal. The activity of 
phosphatidylinositol 3-kinase (PI3K) is required for TGFβ3 stimulation of fusion (203) 
and a recent study discovered that the same is true for ephrin reverse signaling as palates 
stimulated in culture with EphB2/Fc did not fuse in the presence of the PI3K inhibitor 
LY294002. 
The data on ephrin-B2 expression supports the EMT model of palatal fusion in 
that the cells of the ephrin- B2-positive MES was observed in the act of dispersing into 
palatal mesenchyme during fusion. Epithelial cells have a polarized, inflexible 
morphology maintained by specific networks of intermediate filaments, cell-cell 
junctions, and adhesions to the extracellular matrix. The transition to a more fibroblastic, 
motile phenotype such as is observed in the palatal MES, requires the dismantling of 
these networks in favor of a more fluid cytoskeletal arrangement and more plastic cell-
cell contacts. Cytokeratin intermediate filaments disappear in favor of vimentin; laminin-
1 content in the extracellular matrix decreases as fibronectin increases, and E-cadherin 
based adherins junctions are replaced by N-cadherin based cell-cell contacts (204,205). 
These changes in expression are governed by a set of transcription factors such as 
Twist1 and Snail, both of which are regulators of EMT during gastrulation and palate 
development (14,204,206). Thus, EMT involves a reorganization of the cytoskeleton and 
a major shift in gene expression.  
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So, how do ephrins contribute to these events? Part of the answer is found in the 
EMT that is required for metastasis of epithelia-derived tumors (207). In certain settings, 
repulsion between Ephs and ephrins serves to keep potentially cancerous cells within 
their niche, such as in the colon, where ephrins keep intestinal crypt stem cells from 
migrating to the luminal ends of villi to form tumors (199,208). In instances such as 
these, Ephs appear to function as tumor suppressors. In many other cases; however, 
ephrins are upregulated in cancers, and their expression is associated with increased 
EMT and metastasis of malignancies. As mentioned above, the study by Astin et al. 
demonstrated that ephrin reverse signaling enables the loss of contact inhibition seen in 
prostate cancer cells and promotes their migration past normal fibroblasts (201). A novel 
finding of PI3K involvement in ephrin reverse signaling provides a connection to this 
migration mechanism. PI3K signals to Akt, which activates the mTor complex, leading 
to migration of cancer cells. This pathway is frequently activated in malignancies, and 
inhibition of the mTor complex proteins Raptor and Rictor retards cancer cell 
invasiveness and suppresses the EMT required for metastasis (209). This mechanism 
may control the EMT and migration of epithelial cells during palatal fusion (Figure 2-2). 
The PI3K/Akt/mTor system also connects to transcriptional activation associated 
with cancer EMT. The mTor kinase phosphorylates the signal transducer and activator of 
transcription 3 (Stat3) on Ser727, and thereby activates a transcriptional program of 
growth and invasiveness (210,211). Stat3 activation is frequently associated with 
carcinoma invasiveness and poor prognosis (212). Active Stat3 upregulates Twist1 and 
Snail, which in turn suppress E-cadherin expression (206,213). Svoboda et al. 
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demonstrated that Twist1 regulates palatal fusion (214). Thus, PI3K potentially connects 
ephrin-B reverse signaling to an EMT-associated gene expression program in palate. 
Phosporylated ephrin-B1 was also reported to bind directly to Stat3 in embryos 
and tumor cells, suggesting that direct recruitment of this transcription factor to the 
cytoplasmic domain of ephrin-Bs contributes to its activation (215). In addition to being 
a transcriptional activator, the ephrin-B1 cytodomain has been shown to bind the 
transcriptional repressor Groucho/TLE (216). Though the significance of this binding to 
EMT is unknown, Groucho has been reported to repress transcription downstream of 
TGFβ signaling, thus providing another potential cross-interaction with the TGFβ3 
system in palate (217). 
 
Conclusion  
The study of ephrins in palate development is still in its beginnings. It is now 
known that ephrin forward signaling is necessary for early palatal shelf growth, and that 
ephrin reverse signaling is required for fusion of those shelves. But some important 
questions still remain: (1) which Ephs and ephrins control fusion? (2) what are the 
specific downstream effectors of Ephs and ephrins in palatal mesenchyme and 
epithelium? (3) how do TGFβ3 and ephrin signaling pathways intersect? and (4) what 
elements of the transcriptional program in palatal EMT are controlled by ephrin 
signaling? 
  47 
The large collection of molecular and genetic tools available for studying ephrins 
in development makes it certain that efforts to answer these questions will accelerate in 
the coming years, and this will benefit both the fields of craniofacial biology and cancer. 
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CHAPTER III 




Secondary palate fusion requires adhesion and epithelial to mesenchymal 
transition (EMT) of the epithelial layers on opposing palate shelves. This EMT requires 
transforming growth factor β3 (TGFβ3), and its failure results in cleft palate. Ephrins, 
and their receptors the Ephs, are responsible for migration, adhesion, and midline closure 
events throughout development, and both can act as signal transducing receptors in these 
processes (termed "reverse" and "forward" signaling, respectively). Activation of ephrin 
reverse signaling in chicken palates was found to induce fusion in the absence of 
TGFβ3, and that PI3K inhibition abrogated this effect. Further, blockage of reverse 
signaling inhibited TGFβ3-induced fusion in the chicken and natural fusion in the 
mouse. Thus, ephrin reverse signaling is necessary and sufficient to induce palate fusion 
independent of TGFβ3 (218). The data in this chapter describe a novel role for ephrins in 
palate morphogenesis, and a previously unknown mechanism of ephrin signaling. 
 
                                                
 
*Reprinted with permission from “Ephrin reverse signaling controls palate fusion via a 
PI3 kinase- dependent mechanism” by Symone San Miguel,Maria J. Serrano,Ashneet 
Sachar,Mark Henkemeyer,Kathy K. H. Svoboda,M and Douglas Benson, 2011, 
Developmental Dynamics, v.240, 2, 357-364, Copyright 2011 by Wiley-Liss, Inc. 
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Introduction  
 The molecular mechanisms that control mammalian palate development are 
poorly understood. In the mouse, the mesenchymal extrusions of tissue that will 
ultimately form the hard palate elevate over the tongue starting at E11.5. By E14.5, they 
have grown to meet at the midline, at which time the layers of epithelium on the 
opposing shelves adhere (219). Current evidence indicates that these cells then undergo 
epithelial to mesenchymal transition (EMT) and apoptosis to achieve a fused palate of 
confluent mesenchyme, and both these aspects of the fusion process require the action of 
transforming growth factor beta 3 (TGFβ3) (220,221). Kang and Svoboda showed that 
PI3 kinase signaling is required for fusion (222). And recently, Xu et al. demonstrated 
that both Smad4 and p38 MAP kinase act downstream of TGFβ to cause palate fusion, 
although either alone appeared dispensable (41,218). 
 Early migration of embryonic neural crest cells that form the mouse palate 
require the action ephrin-B1, and its cognate Eph receptors (218,223). The Ephs are the 
largest family of receptor tyrosine kinases (RTKs), and are subdivided into A and B 
groups based on their preferential binding to the glycosylphosphatidyl inositol-linked A 
ephrin or the transmembrane B ephrin ligands, although binding can be promiscuous 
across classes (218,224). Ephrins are unique among RTK ligands in that they can also 
act as receptors, with the Eph acting as ligand, a process called “reverse signaling” 
(194,218). In humans, ephrin-B1 mutations are associated with syndromes that include 
CP (225-227), highlighting a likely conserved role for ephrin signaling in palate 
development. Recent work by Risley, et al. reported a role for EphB forward signaling in 
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the proliferation of palate shelf mesenchyme prior to midline apposition (49,218). This 
study was closely followed by a report from Bush and Soriano (2010) showing that 
ephrin- B1 forward signaling controls NCC-derived mesenchyme proliferation through 
the mitogen-activated protein kinase (MAPK) pathway (218). These findings are 
consistent with known roles for EphB forward signaling in progenitor proliferation in 
other systems, such as the hippocampus and the intestine (208,228). Both the Risley et 
al. (2009) and the Bush and Soriano (2010) studies showed evidence of Eph and ephrin 
in palate at a stage when the shelves begin to undergo EMT and fuse (218).  
Risley et al. (2009) reported Ephs B2 and B3 and all three B ephrins in mouse 
palate epithelium and mesenchyme at E14.5, and Bush and Soriano (2010) showed 
ephrin-B1 at the same stage, only in the mesenchyme.  Ephs and ephrins direct midline 
adhesion and fusion events in other developmental processes, such as urethral closure 
and urorectal septation (195,218). Thus, the question is whether they play a similar role 
in palate fusion. Here, in this chapter it is documented that the expression of B Ephs and 
ephrins in pre-fusion palate epithelium and the requirement for ephrin reverse signaling 
in palate fusion. The findings describe a novel role for ephrins in craniofacial 




TGFβ3 was obtained from Invitrogen (Carlsbad, CA). LY294002 PI3K inhibitor 
was from Cell Signaling Technology (Danvers, MA). EphB2 ectodomain was from 
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R&D Systems (Minneapolis, MN). IgG Fc protein was from Calbiochem (EMD 
Chemicals, Gibbstown, NJ) (229). Ephrin-B2 ectodomain fused to human Fc was 
produced by cloning a PCR product encompassing the extracellular portion of the coding 
sequence for murine ephrin-B2 into pFUSE-hIgG1e3-Fc2 (InvivoGen, San Diego, CA). 
The resulting plasmid was transfected into CHO-K1 cells (ATCC). Fusion protein was 
collected from conditioned supernatant by protein A chromatography and analyzed by 
Western blot with anti-Fc antibody (Jackson Immunoresearch). Detailed cloning and 
purification protocols available upon request. Fc clustering was accomplished with the 
same anti-Fc antibody (218). 
Embryonic Palate Culture 
Chicken palate culture was performed as previously described (203). Briefly, 
palate shelves were dissected from eight day old chicken embryos and placed nasal side 
down on nucleopore polycarbonate membranes and cultured with in BGJb medium 
(InvivoGen, San Diego, CA) for 72 h in 37oC with 5% CO2. Medium was replaced 
every 24 h with fresh treatments. TGFβ3 was used at 50 ng/ml. EphB2, ephrin-B2, and 
control IgG Fc proteins were used at 5 ng/ml. EphA4/Fc was used at 20 ng/ml (218). 
IgG Fc was added at 20 ng/ml when used as control for EphA4/Fc. LY294002 was used 
at 10 µM. To cluster Fc proteins, protein was mixed with anti-Fc in a 4 to 1 w/w ratio as 
a 50x or 100x stock and incubated at 22C for 1 h or overnight at 4C (218,230). 
Histological Analysis 
Cultured palates were fixed in 4% formaldehyde/phosphate buffered saline for 2 
days. They were then stabilized in low melting point agarose and processed for paraffin 
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embedding. Serial 6 mm sections were collected in the coronal orientation from anterior 
to posterior. Sections were stained with hematoxylin and eosin (H&E) and photographed 
on a light microscope with a digital camera (229). Every twentieth section was scored 
for fusion by at least two independent, blinded observers using the previously described 
scale (Kang and Svoboda, 2002) (203):  1=non-fusion with no adhesion, 2=non-fusion 
with some apparent adhesion, 3=partial adhesion with some disintegration of MEE 
layers, 4=complete fusion with some traces of MEE cells or seam remaining, 
5=complete fusion with no evidence of MEE cells or seam visible (229). 
 
Results 
Eph and Ephrin Expression in Fusing Palate Epithelium 
 The expression of beta-galactosidase (βgal) was examined in mouse embryos 
that were genetically engineered to express a chimeric ephrin-B2 allele in which the 
intracellular domain was replaced by a βgal moiety (218,231). At E14.5, ephrin-B2/βgal 
specifically was found in the palate epithelial cells, many of which had begun to migrate 
inward to mix with mesenchymal cells in the interior of the shelf (Figure 3-1A). This 
migration parallels the previously documented movement of fluorescently labeled 
epithelial cells during the EMT process that leads to fusion (192,218,232) and validates 
ephrin-B2 as a marker for palate epithelium. It was also noted βgal expression in the 
same layer in the EphB2/LacZ mouse, in which the lacZ gene replaces the EphB2 allele 
(218,233) (Figure 3-1B). These data suggested that Eph/ephrin forward and/or reverse 
signaling in the epithelial layers may play a role in palate adhesion and fusion (229). 
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Activation of ephrin reverse signaling causes palate fusion 
To examine the role of ephrins in palate fusion, It was employed a well 
established ex vivo chicken palate culture system. The chicken palate does not naturally 
fuse, unlike the mouse palate. However, the palate shelves will fuse if placed in contact 
and given exogenous TGFβ3 (234). In this respect, the functional difference between 
mouse and chicken is that the mouse palate makes its own TGFβ3 (218,235); anti-TGF 
antibodies will block mouse palate fusion (40,218). Thus, the chicken system allows to 
examine ephrin signaling apart from TGFβ3 simply by adding or withholding this factor. 
To stimulate Eph forward signaling, purified recombinant ephrin-B2 extracellular 
domain fused to human Fc was used. In order for this protein to be biologically active, it 
must be artificially clustered by the addition of anti-Fc antibody to stimulate the receptor 
aggregation that is required to initiate intracellular signaling (218,230). The protein was 
applied, with or without TGFβ3, to palate shelves placed in contact for 72 h. The tissues 
were fixed and evaluated them histologically for fusion using the previously published 
one to five scale for mean fusion score (MFS) (203). Palates treated with IgG Fc as a 
negative control did not fuse (MFS=2.2±0.20), while those treated with TGFβ3+IgG Fc 
fused as expected (MFS=3.6±0.20; Figure 3-2). In comparison, palates treated with 
clustered ephrin-B2/Fc exhibited mildly increased partial fusion (MFS=2.6±0.23)(218). 
 More dramatic results were observed when the palates were treated with 
clustered EphB2/Fc recombinant protein to activate reverse signaling through 
endogenous ephrin-Bs. Clustered EphB2/Fc gave an MFS of 3.4±0.24, essentially 
equivalent to TGFβ3 treatment. When applied without clustering, Eph and ephrin Fc 
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proteins serve as effective blocking reagents because they bind to their target ligands and 
receptors without activating biological signaling, thus acting as competitive inhibitors 
(218,236). This strategy was employed by adding unclustered EphA4/Fc to palate 
cultures. EphA4 binds to all A and B ephrins and so serves as a good pan-ephrin blocker 
(237). This treatment effectively blocked palate shelf fusion, even in the presence of 
TGFβ3 (MFS=2.1±0.13; Figure 3-2). Thus, these data indicate that ephrin reverse 
signaling is required for palate fusion and is genetically downstream of TGFβ3 (218). 
 If this role of ephrins in fusion is conserved in mammals, then it would expect 
that inhibiting ephrin action in mouse palate would prevent the naturally occurring 
fusion normally observed in culture (218). To test this prediction, unclustered EphA4/Fc 
to E14.5 mouse palate culture was applied, and observed the same effect as in the 
chicken:  an inhibition of palate fusion (MFS=2.55±0.12 vs 4.26±0.08) (Figure 3-3. 
Interestingly, it was observed in the mouse that fused areas were interspersed with non-
fused areas along the length of touching epithelium. Nevertheless, the data clearly 
demonstrate that the requirement for ephrin signaling is conserved between chicken and 
mouse (218). 
Ephrin-Dependent Fusion is PI3 Kinase Dependent 
 The palatal culture evidence indicated that ephrin signaling in palate fusion acts 
downstream of the receptor for TGFβ3. As noted above, previous work showed that 
TGFβ3-induction of fusion requires active PI3K, as PI3K inhibition abrogates or delays 
fusion (218). This would appear to place a required TGFβ3 effector downstream of 
ephrin signaling. Therefore it was tested whether ephrin reverse signaling also acts 
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through PI3K. Chicken palates cultured in the presence of the PI3K inhibitor LY and 
either TGFβ3 or clustered Eph-B2 failed to fuse over the test period (Figure 3-4). Thus, 




Collectively, this study shows that ephrin reverse signaling is both required and 
sufficient for chicken palate fusion, and that PI3K is part of this signaling mechanism. 
As the stimulating and blocking reagents used here are not specific to a single Eph or 
ephrin member, we are not able to identify the individual ephrin that mediates fusion, or 
even whether t is a single or multiple ephrins (218). We do not know from our own 
experiments the expression of the remaining B ephrin, ephrin-B1, in the fusing palate. 
Our expression data for EB2 and EphB2 conflict with those of Risley et al., which 
reported all three B ephrins and EphB2 in both epithelium and mesenchyme at e14.5 
(49).  Although ephrin-Bs are more likely candidates for receptors of the EphB2 used in 
experiments (193,194,218). EphB2 is activated by at least one ephrin-A ligand (238). 
The initial expression evidence does suggest ephrin-B2 as the most likely candidate due 
to its presence in the midline epithelium at the time of palate contact. As mentioned, the 
observed migration of ephrin-B2/LacZ expressing cells into the mesenchyme during 
fusion parallels that seen in MEE cells labeled with vital dyes (239), and defines ephrin-
B2 as a marker of these cells (218). 
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Another important question is how the signaling pathways of TGFβRs and 
ephrins intersect within cells of the fusing palate. Up to now, study of signal 
transduction in palate fusion has focused on events downstream of TGFβ3, as this was 
thought the chief requisite growth factor for EMT and fusion (218,221,240). The chicken 
palate findings show that ephrin signaling is downstream, or at least independent of, 
TGFβR signaling in that it was possible to dispense with the TGFβ3 treatment. It is now 
know that the PI3K mechanism is a point of intersection, but the up-and downstream 
details of the interaction are unknown (Figure 3-5) The action of the transcription factors 
Twist1 and Snail were shown by Yu et al. to mediate at least a substantial part of 
TGFβ3’s fusion-promoting activity, as RNAi against these genes’ mRNAs partially 
inhibited fusion (218,241). It will remain to be seen whether ephrin reverse signals 
impact these factors as well. 
The EphA4/Fc blocking experiments demonstrated that the ephrin requirement is 
conserved between mouse and chick (218). However, previous data suggests that ephrins 
may not be sufficient in the mouse. Blocking antibodies against TGFβ3 inhibit mouse 
palate fusion, and genetic ablation of TGFβ3 in mice yields cleft secondary palate 
(34,40,220,235). This suggests that endogenous ephrin signals are not sufficient to 
compensate for loss of TGFβ3 (218). Thus, there may be a difference in the hierarchical 
roles of TGFβ3 versus ephrins between the two species. Alternatively, ephrin expression 
in the palate epithelium may be under the control of TGFβ3 such that loss of the TGFβ3 
signal eliminates the endogenous ephrin signal as well (218). 
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The findings in this study have broader implications for ephrin biology beyond 
the example of palate fusion. Ephs are known to mediate EMT in other processes, such 
as cancer metastasis, and although PI3K signaling was implicated in Eph/ephrin systems, 
it was in the forward direction, downstream of the Eph RTKs (199,218). There is a 
report of PI3K being required for in vitro ephrin induced proliferation in an endothelial 
cell line via reverse signaling (242), but this work is the first evidence of reverse 
signaling mediating a biologically critical developmental EMT event via PI3K. Although 
PI3K is associated with cell motility, and ephrin reverse signaling is associated with cell 
migrations, this pathway has not been connected with the known signaling elements of 
the ephrin-B cytoplasmic domain (218). 
The cytoplasmic domains of B class ephrins contain conserved tyrosines that are 
phosphorylated upon stimulation to form SH2-binding domains that bind the adaptor 
Grb4 (218,243), although it is possible they may bind other SH2 domain proteins in 
different contexts. Grb4 complexes with other factors such as the GTPase activating 
protein 1 (GIT1) and Glutamate receptor interacting protein 1 (GRIP1) in the case of 
synapse formation (218,244,245). B ephrins also have a C-terminal PDZ-binding 
domain, which is required for a number of biological functions (47,246). Binding of SH2 
proteins in the PI3K pathway to ephrin-B2 is certainly plausible, but not yet 
demonstrated. A-class ephrins, on the other hand, do not have cytoplasmic domains. 
Still, they can participate in reverse signaling via a co-receptor (218,247,248). Of course, 
it is also possible that the reverse signal does not directly activate PI3K, but promotes is 
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action indirectly (218). This finding therefore encourages increased investigation along a 
new direction of ephrin signaling. 
The ongoing studies will focus on identification and regulation of the specific 
Eph and ephrin molecules involved in palate fusion, the signal transduction pathways 
downstream of those ephrins, and their intersection with TGFβR-mediated pathways 
(38,218). 
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CHAPTER IV 
EPHRIN REVERSE SIGNALING MEDIATES PALATAL FUSION AND 
EPITHELIAL-TO-MESENCHYMAL TRANSITION INDEPENDENTLY OF TGFβ3 
 
Synopsis 
The mammalian secondary palate forms from shelves of epithelia-covered 
mesenchyme that meet at midline and fuse. Failure of the midline epithelial seam (MES) 
to degrade blocks fusion and causes cleft palate. It was previously thought that 
transforming growth factor β3 (TGFβ3) is required to initiate fusion. Members of the 
Eph tyrosine kinase receptor family and their membrane-bound ligands, the ephrins, are 
expressed on the MES. It was discovered that activation of ephrin reverse signaling 
(where the ephrin acts as a receptor and transduces signals from its cytodomain) was 
sufficient to cause fusion in cultured mouse palates and epithelial-to-mesenchymal 
transition (EMT) in palatal epithelial cells, even in the absence of TGFβ3 signaling. In 
this chapter, cultured mouse palates in the presence of either a blocking antibody against 
TGFβ3 or an inhibitor of the TGFβrI serine/threonine receptor kinase were shown. 
Fusion was abolished by both treatments, but was significantly rescued by the addition 
of EphB2/Fc recombinant protein to activate ephrin reverse signaling. Cultured palate 
epithelial cells traded their expression of epithelial cell markers for that of mesenchymal 
cells after treatment with EphB2/Fc and became motile. They concurrently increased 
their expression of the EMT-associated transcription factors Snail, Sip1, and Twist1. The 
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data confirm that ephrins direct palatal fusion in mammals and activate a gene 
expression program not previously associated with reverse signaling. 
 
Introduction  
The secondary palate in humans and mice forms from shelves of mesenchyme 
covered by epithelium. These shelves grow out bilaterally from the internal surfaces of 
the maxillary processes, elongate on each side of the tongue and become horizontal 
above the tongue as it descends (249,250). As soon as the opposing shelves reach each 
other, the lateral surfaces of the medial edge epithelia (MEE) cells form the medial 
epithelial seam (MES) (249,251). Complete disintegration of the MES is essential to 
form a confluent structure, and failure of palatal fusion causes CP, one of the most 
common birth defects (252). Thus, understanding the mechanism of fusion is an 
important goal of craniofacial biology. 
 Palatal fusion has been thought to require Transforming Growth Factor β-3 
(TGFβ3) because TGFβ3 knockout mice, as well as naturally TGFβ3-null avian systems, 
display CP, and treatment of either with exogenous TGFβ3 rescues palatal fusion 
(234,253,254). Genetic and phamacological studies have shown that the TGFβ3 signal, 
acting through serine/threonine kinase TGFβ receptors (TGFβr) on MEE cells, activates 
Smad, p38 mitogen-activated protein kinase (MAPK) and phosphotidyl inositol 3 kinase 
(PI3K) pathways in palate epithelium (255,256). Fusion requires PI3K and either (but 
not necessarily both) the Smad or p38 pathways (255). However, the mechanism of MES 
degradation is still in question. Numerous studies suggest that the epithelial cells 
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undergo epithelial-to-mesenchymal transition (EMT), apoptosis, or both (thoroughly 
reviewed in (250). Recent work on cultured primary MEE cells indicates that TGFβ3 
causes these cells to shift gene expression patterns away from epithelial markers to 
fibroblastic ones, while assuming a migratory phenotype (the definition of EMT). They 
then initiate caspase-dependent apoptosis. This entire process occurs in culture over the 
same 72 h time frame as does fusion in the mouse embryo, consistent with a mechanism 
that is reflective of the actual process in vivo (257). 
 It was recently reported a role for ephrin signaling in palatal fusion. The Ephs are 
the largest family of receptor tyrosine kinases. They are classified as A or B based on 
sequence homology and on their binding preference for the transmembrane B ephrin or 
the glysosyl phosphotidyl inositol linked A ephrin ligands (258). Eph-ephrin systems 
control a number of contact-dependent processes in development, including cell 
migration, boundary formation, and proliferation (198,259,260). Ephs function as 
traditional receptor tyrosine kinases when bound by their ephrin ligands, but they can 
also act as ligands that activate signaling downstream of the ephrin, which assumes the 
role of receptor in what is called "reverse signaling" (261). EphB and ephrin-B 
expression was reported in the MEE during fusion, and that ephrin-B reverse signaling 
was found to be required for palate fusion in mice and is sufficient to cause fusion in 
chicken palates without TGFβ3 (218). This finding was supported by a report of CP in 
ephrin-B2 reverse signaling-deficient mutant mice (200). Interestingly, it was discovered 
that the ephrin reverse signal passes through PI3K, a signaling pathway not previously 
associated with reverse signaling (218). 
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 It was found that activation of reverse signaling in mouse palates is sufficient to 
cause fusion independently of TGFβr, and that the ephrin signal activates an EMT-like 
program in palatal epithelial cells. This data describe a role for ephrins in craniofacial 
development, and help to clarify their role in palatal fusion. 
 
Experimental Procedure 
Chemicals and Reagents 
Anti-TGFβ3 was obtained from R&D Systems (Minneapolis, MN). The TGFβrI 
Kinase Inhibitor VI (SB431542) was from Calbiochem (EMD Millipore Cat#616465) 
(Billerica, MA). EphB2 ectodomain Fc fusion protein was from R&D Systems (Cat 
#467-B2) (Minneapolis, MN). IgG Fc protein was from Calbiochem (EMD Millipore 
Cat #401104) (Billerica, MA). Exogenous recombinant TGFβ3 (R&D systems, CA). For 
Immunofluorescence, primary antibodies used (and their source) included the following: 
E-Cadherin, Desmoplakin and Plakoglobin (kindly provided by Dr. James Wahl, 
University of Nebraska Medical Center), Vimentin (Sigma-Aldrich, MO), Fibronectin 
(Abcam, MA), ZO-1 (Invitrogen, CA), All antibodies and inhibitors were used at the 
concentration and time point recommended by the respective manufacturer/provider 
(262). 
Embryonic Palate Culture 
Mouse palate culture was performed as previously described (204,218,256). In 
brief: Palatal shelves were dissected from E13.5 CD1 mouse embryos and placed nasal 
side down on polycarbonate membranes (Nucleopore Corp.) with their medial edges in 
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contact. The tissues were cultured with BGJb medium (Gibco) for 72 hrs (214). Medium 
was replaced every 24 hr with fresh treatments. Anti-TGFβ3 was used at concentration 
of 10µM. TGFβrI Kinase Inhibitor VI (SB431542) was used at a concentration of 25 
µM. Based on the initial dose-response experiments (not shown), this was the 
concentration of kinase inhibitor that abolished MES degradation in cultured palates 
while showing no signs of altered cell morphology. EphB2/Fc and control IgG Fc 
proteins were used at 5 µg /ml, as in previously published studies. Fc proteins were 
clustered by mixing with anti-human Fc in a 4 to 1 w/w ratio and incubated at 22ºC for 1 
hr or overnight at 4ºC. This treatment allows the soluble Fc proteins to mimic the 
clustering that occurs on cell membranes and is required to initiate biologically relevant 
signaling.  
Histological Analysis 
Cultured palates were fixed in 4% formaldehyde/phosphate buffered saline, 
stabilized in low melting point agarose, and processed for paraffin embedding. Serial 6-
µm sections were collected in the coronal orientation from anterior to posterior 
(30,218,232). Sections were stained with hematoxylin and eosin (H&E) and scored for 
fusion by at least two independent blinded observers using the previously described 
scale as follows (256):  A score of 5 denotes complete fusion with no epithelia persisting 
in the midline. A score of 4 means epithelial triangle or islands remained, but they are 
less than 1/3 the total width of the palatal shelf interface(214). A score of 3 signifies 
mesenchymal confluence was achieved in places, but over 1/3 or less of the palatal shelf 
interface, with large epithelial islands or triangles remaining. A score of 2 means that a 
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continuous epithelial seam persisted in the midline. Palatal shelves that were not 
touching each other in the midline received a score of 1. 
Statistical Analysis 
Palate Culture Experiments: All palate fusion experiments were performed at 
least three times for a total n=12 to 18 for each treatment group. Fusion scores reported 
are the mean ± standard error of the mean (SEM) of the pooled scores across all 
experiments. Statistical analyses were made using SPSS software. Mean Fusion Scores 
were analyzed using Kruskal–Wallis test with the Mann-Whitney U test used to analyze 
specific sample pairs for significant differences. Differences in fusion score between 
groups with p<0.01 were considered to be statistically significant. The statistical power 
of the samples in experiments was evaluated by G*POWER software (Version 3.1). The 
power with respect to the seriousness of types I and type II errors rate was calculated 
with the settings type I error, α = 0.01 and type II error, β=0.05. It was expected that the 
power analysis under these settings and with a sample size large enough would yield a 
statistically significant effect.  
Palate Culture Experiments: Data from at least three replicates for each 
parameter were evaluated and analyzed for signiﬁcance by SPSS 14.0. The treatment 
groups included TGFβ3, EphB2/Fc and the control groups (IgG Fc). The observation 
times were collapsed due to the convenience of the study, and one-way ANOVA was 
conducted. The signiﬁcance level was set as 0.05. AP-value of ≤0.05 was considered 
signiﬁcant. The one-way ANOVA indicated that the values differ signiﬁcantly across the 
treatment groups. Bonferroni post-hoc comparisons of the treatment groups indicated 
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that the negative control control group signiﬁcantly differ from each other (P≤0.005). 
The comparison of each treatment group (time and dose) showed EphB2/Fc treatments 
groups also differed signiﬁcantly from the negative control groups (P≤0.005). 
Culture of Isolated Primary MEE Cells 
The following four experiments were designed and discussed at Baylor College 
of Dentistry, in the Department of Biomedical Sciences. However, these were done as 
collaboration with Jingpeng Liu at the University of Nebraska Medical Center. 
Embryonic MEE cell culture was performed as previously described (249,257,263,264). 
The single cell thick periderm covering on each shelf was removed by incubating the 
shelves with Proteinase K for 1hr at 37oC. The shelves were then cultured at 37oC for 12 
hrs to allow brief adherence to the corresponding opposite shelf (adhered). Adhered 
shelves in organ culture were then cut close to the seam to ensure limited or no 
mesenchymal tissues attached to isolated seam (265). The shelves were then separated 
and treated with Dispase II for 30 min to allow the primary MES cells to separate from 
the underlying basement membrane so that epithelial cells could be collected without 
any mesenchymal contamination. Cells were then cultured in flasks and harvested at the 
exponential growth stage (∼80% confluence) before any exogenous treatment began 
(265). 
Scratch-Wound Assay 
The Scratch Wound Assay was conducted as previously described (263). MES 
cells were grown to 80% conﬂuency in 6-well culture plates, and a uniform straight line 
scratch was made with a sterile pipette tip (249). Scratches in EphB2/Fc (2, 5 and 10 
  66 
µg/mL) treated and IgG Fc (control) wells were examined for 48h. The migration of 
cells (or gap ﬁlling) was monitored every 12h with phase contrast microscopy where 
cells were morphologically assessed for the migratory phenotype (249). 
Cell Motility Assay 
The Cell Motility Assay was conducted reported (263). 8 µm pore size Transwell 
migration chambers of a 6-well plate (BD BioCoat, MA) were used for migration 
analyses. 5×105 MES cells were seeded in the presence of 5mg/mL EphB2/Fc in 8µm 
pore size Transwell migration upper chambers of a 6-well plate. Treated and control (Ig 
Fc) MES cells were allowed to migrate through the filter toward media containing serum 
(10%) for 24 to 48 hours at 37 °C. Cells that did not migrate through the filter were 
removed with a cotton swab from inside the upper chamber. Each filter was fixed in 4% 
Paraformaldehyde for 10 minutes, washed three times, each time for five minutes with 
1x PBS, placed in Hematoxylin stain (Dako, Mayer’s hematoxylin) for 20 minutes, 
rinsed with water, and placed in bluing reagent (alkaline solution such as a weak 
ammonia solution, 0.08% in water) until the stain turned blue. Subsequently, the filters 
were washed again using deionized water. Migrating MES cells on the lower side of the 
filter were randomly counted at 10 areas per field by phase-contrast microscopy. The 
mean of the 10 areas was determined and is represented in the bar graph in Fig. 4B 
Immunohistochemistry, Immunoﬂuorescence, and Immunobloting 
The MES cells and embryonic palates from 14.0 to 16.5 dpc underwent 
Immunohistochemistry, Immunoﬂuorescence and Immunoblotting techniques as 
described previously (249,257,263,264). For protein expression of MES cells by western 
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blot, the cells were grown to conﬂuency in 10% FBS and serum starved in 1% FBS for 
24 h, followed by treatment with TGFβ3 (2 and 5 ng/ mL) and EphB2 ( 2 and 5µg/mL) 
in 1.0% FBS DMEM for 0–24 h for total protein extraction. For total proteins, the 
nuclear extraction kit from Chemicon total protein Extraction Kit (Millipore) was used 
as done previously (257,264). The concentration of the total proteins was obtained with 
the Genesys 10 UV scanner (Thermoscientiﬁc) at 595 nm. The 25µg of protein extract 
was electrophoresed on a 10% denaturing gel and transferred onto a nitrocellulose 
membrane. The membranes were blocked with gelatin, washed with PBS-Tween, 
incubated with the EphB2 (Source) and TGFβ3 (R&D Systems) antibodies and reacted 
with anti-goat (1:1000) and anti-rabbit (1:2000) secondary antibodies (Cell Signaling). 
The bands were then visualized by using an odyssey scanner (Li-Cor). Intensity of the 
band was measured using the Carestream Molecular Imaging Software version 5.3.1 
(Rochester). To perform a t-test analysis of mean intensity measurements, an ROI 
analysis was done from the data to Microsoft Excel software from the exported “.txt” 
ﬁles. Data points for all samples are paired by spatial arrangement on gel and compared 
pairwise to minimize the impact of subtle background artifacts on image analysis. For 
protein expression on embryonic palates, 8µm sections of 14.5 dpc palates from WT and 
TGFβ3 knockout mice underwent Immunohistochemitsry as well as MES cells 
underwent Immunoﬂuorescence as described previously (257,263,266). 
Immunoﬂuorescence secondary antibodies were obtained from: Rhodamine, 1:100 
(Invitrogen) and FITC, 1:200 (Jackson ImmunoResearch).  
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Gene Expression 
As described previously, (267,268) RNA from MEE cells treated with clustered 
EphB2/Fc (1, 2, or 5 µg/ml) for 48 h, was harvested using the RNeasy Mini Kit (Qiagen, 
CA) according to the manufacturer’s instructions. RNA integrity was assessed using 
formaldehyde gels in1XTAE buffer, and RNA purity and concentration were determined 
by the 260/280 ratio on a Nanodrop 2000C (Thermoscientiﬁc, MA). The Ct values were 
exported into a Microsoft Excel Spreadsheet and analysed according to the ΔCt system. 
The –ΔΔCt (Snail, Sip1, Twist and E-Cadherin/vs IgG Fc control) values were plotted to 
show the genes that are up or downregulated in fold/s increase.  
The sequences of primers were obtained from the Invitrogen online PCR primer 
design site, and were synthesized at the Molecular Biology Core Facility, UNMC. 
 
Mouse Snail   5’- TGAGGTACAACAGACTATGCAATAGTTC -3’  
   5’- CCTGCTGAGGCATGGTTACA -3’  
Mouse Twist   5’- TCCGCGTCCCACTAGCA -3’  
   5’- TTCTCTGGAAACAATGACATCTAGGT -3’  
Mouse Sip1   5’- TTGTGCCCATCACGAAAAAG -3’  
   5’- GTGCACAGTTTGACAATTTAATTGAA -3’  
Mouse E-cadherin,  5′-AAGTGACCGATGATGATGCC-3′ 
   5′-CTTCTCTGTCCATCTCAGCG-3′. 
 
Gene expression was determined by normalization with the control gene, 
GAPDH. Each RT-PCR experiment was performed in triplicate. 
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Results 
Ephrin Reverse Signaling Mediates Palatal Fusion Independently of TGFβ3. 
 It was previously reported that exogenous ephrin activation causes fusion in 
chicken palates without the need for TGFβ3 (218). The questions then arises on whether 
the same is true of mouse palates if the TGFβ signal is romoved. This question can be 
answered in two ways using the mouse palate culture system. These experiments were 
preformed by placing embryonic mouse palatal shelves in contact on a support, and 
observing MES degradation and fusion over 72 h. After histological processing, each 
palate was scored for fusion on a one to five scale to generate a mean fusion score 
(MFS) for anterior, middle, and posterior regions, as detailed above. First, a set of 
embryonic mouse palates was cultured in the presence of a blocking antibody against 
TGFβ3 with or without clustered EphB2/Fc protein to activate ephrin-B reverse 
signaling (preclustering with anti-Fc is necessary to induce signaling). Secondly, another 
set with a chemical inhibitor of the TGFβr kinase (SB 431542) was cultured, again with 
or without EphB2/Fc. Control palates in the anti-TGFβ3 experiment fused normally over 
the three-day time window of these experiments, although fusion was on average 
incomplete in the posterior region (MFS±SEM= 4.5±0.08 for anterior, 4.6±0.09 for 
middle and 3.0±0.24 for posterior regions; Fig.4-1). Antibody treatment abolished MES 
degradation and palatal fusion (MFS=1.4±0.08 anterior, 2.0±0.10 middle, and 1.3±0.23 
posterior; Fig. 4-1A) such that the epithelial layers in the MES remained almost entirely 
intact (Fig. 1B). Kinase inhibitor treatments had the same effect of abrogating fusion 
(MFS= 1.2±0.13 anterior, 1.7±0.20 middle, and 1.1±0.11 posterior with SB 431542 vs. 
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MFS= 3.5±0.17 anterior, 4.7±0.22 middle and 3.4±0.10 posterior for untreated controls; 
Fig. 1B and D). In both cases, addition of recombinant EphB2/Fc restored wide spread, 
though not complete, seam degradation and largely rescued fusion (MFS= 2.6±0.17 
anterior, 3.9±0.11 middle, 2.6±0.08 posterior for anti-TGFβ3+EphB2, and 
MFS=1.9±0.08 anterior, 3.8±0.11 middle, 3.0±0.20 posterior for SB 431542+EphB2; 
Fig. 4-1A and C). Thus, although fusion was not restored to control levels, these data 
demonstrate that exogenous activation of ephrin reverse signaling is capable of causing 
MES degradation and palatal fusion in the absence of a TGFβ signal. 
 Results indicated that ephrins are downstream of TGFβ3 in palatal fusion, and so 
the possibility that TGFβ3 may simply activate Eph expression in the MEE to cause the 
fusion signal was investigated. Because it is known that EphB2, at least, is capable of 
acting as a ligand to induce fusion, its expression in the palatal MEE in the absence of 
TGFβ3 was examined. As shown in Figure 4-2A, EphB2 protein expression levels were 
found in the palates of TGFβ3 knock out mice were comparable to those in wild type 
mice. Further, primary palatal MEE cells was cultured in the presence of either TGFβ3 
or clustered EphB2/Fc, and found that TGFβ3 did not appreciably increase EphB2 levels 
on Western blot, nor did EphB2 increase TGFβ3 protein (Fig. 2B). Therefore, it can be 
concluded that it is likely not the role of TGFβ3 in fusion to simply induce Eph 
expression and thereby initiate fusion. 
 It was previously found that MEE cells in fusing palates show signs of epithelial 
to mesenchymal transition (EMT), and that TGFβ3 added to MEE cells in culture causes 
EMT-like phenotypic changes, cell migration, and gene expression (218,257). The 
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behavior of these cells after activation of the ephrin reverse signal was examined to 
investigate the mechanism of ephrin function in fusion. MEE cells grown to confluence 
exhibit the hallmarks of epithelial cells:  tightly packed, cuboidal cells joined in a sheet 
by desmosomes and tight junctions. E-cadherin, desmoplakin, and plakoglobin are 
among the proteins that are conspicuously and highly expressed in these epithelia-
specific junctions. After 24 h of exposure to clustered EphB2/Fc, the expression of these 
proteins was markedly diminished, and by 48 h, largely disappeared (Fig. 3A). At the 
same time, fibronectin and vimentin, both fibroblast markers, rapidly increased on the 
cell surface (Fig. 3B). EphB2/Fc-treated cells also lost their tight packing over this time 
and assumed a looser, mesenchymal shape (Fig. 3A and B). 
 At the same time as these cells were changing their cell junction compositions 
and morphology, they became more motile. A scratch-wound assay on monolayers of 
MEE cells was performed to be treated with EphB2/Fc or control Fc. Fig. 4A shows that 
substantial numbers of EphB2/Fc treated cells moved into the cleared scratch area over a 
48 h period, whereas control cells moved very little. By 48 h of treatment, it was 
observed a six-fold increase in motile cell number in EphB2/Fc cultures over that 
observed in controls (Fig. 4B). It can be concluded that activation of ephrin reverse 
signaling in MEE cells causes them to assume a mesenchymal phenotype. 
 The EMT that was observed requires a shift in gene expression, and so the levels 
of some key transcription factors were examined to be associated with gene expression 
profile changes in EMT. Both the basic helix-loop-helix (bHLH) transcription factor 
Snail and the Smad-interacting protein 1 (Sip1) are upregulated during developmental 
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EMT and have been shown to repress E-cadherin expression (249). It was recently 
shown that the EMT-associated bHLH factor Twist1 is also upregulated during palatal 
fusion and plays a role in MES degradation (204,269,270). Therefore it can be quantified 
the mRNA levels of these three genes in MEE cells after 48 h of EphB2/Fc treatment 
using real-time PCR. Snail mRNA doubled at the 5 µg/ml dose of EphB2/Fc used for 
palate and MEE culture experiments, and Sip1 increased more than 5-fold versus 
control. Although Twist1 mRNA increased only 30%, the change was significant and 
reproducible (Fig. 5). At the same time, E-cadherin mRNA was reduced 60% compared 
to control. This result is consistent with a role for ephrin reverse signaling in activation 
of the EMT gene expression program in MEE cells. 
 
Discussion 
 It was previously showed that ephrin reverse signaling is required for mouse 
palatal fusion (218). Here it can be shown that it is sufficient to cause fusion in the 
absence of TGFβ3, a growth factor that was previously considered indispensible for 
fusion. Further, it can be proved that the ephrin signal causes EMT in palatal epithelial 
cells. These findings are significant for three reasons. First, the fact that ephrins cause 
EMT in palatal epithelial cells adds significance to the argument that palatal fusion 
proceeds through an EMT mechanism. Second, the discovery that ephrin signaling 
during fusion is separate from, and can supersede, TGFβ3 shifts the focus of intracellular 
signaling away from purely those pathway intermediates affiliated with the TGFβr 
serine/threonine kinase receptor. Third, the association of ephrin reverse signaling with 
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EMT reveals a previously unknown role for ephrins in activation of a gene expression 
program. 
 There are two prevailing theories of the mechanism of MES degradation in 
palatal fusion. One argues that the MEE cells proceed through EMT to achieve 
mesenchymal confluence in the palate (232,234,270-273). The other says that these cells 
are removed by apoptosis to allow the mesenchyme to join (274-276). Both of these 
views have been supported with strong evidence. Recent data suggest that these theories 
are not mutually exclusive. Ahmed, et al. reported that MEE cells in culture exposed to 
TGFβ3 undergo EMT, with appropriate changes in morphology and gene expression, 
followed by apoptosis (257). Their studies are consistent with genetic evidence from 
mouse studies of palatogenesis. Jin and Ding showed that Apaf1 knockout mice, while 
deficient in apoptosis, developed fused palates, indicating that fusion does not rely on 
apoptosis alone. However, histological examination revealed that the triangles of 
epithelial cells normally found at the oral and nasal edges of fusing palates persisted in 
Apaf1 knockouts, whereas they eventually disappear in wild type animals (277). These 
same triangles were observed by Ahmed and coworkers in cultured palates treated with a 
caspase inhibitor. Thus, it would seem that both EMT and apoptosis combine to remove 
the MEE cells and complete palatal fusion. This finding that EphB2 treatment both 
induces fusion and initiates EMT in MEE cells independently of TGFβ3 reinforces the 
view that EMT is a part of the fusion mechanism. Ephrin-B signaling has been shown to 
induce apoptosis in other systems (278,279), and it will be interesting to discover in the 
ongoing studies if it does so in the palate. EphB2 treatments did not completely rescue 
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fusion in TGFβ-blocked palates, and this observation could be explained by an 
insufficiency of ephrin reverse signaling to activate a specific part of the fusion program, 
such as an apoptotic activity that removes remaining MEE cells. Alternatively, it could 
be that there is a TGFβr-specific signal (e.g:  one that is Smad-associated) that, while not 
formally required for fusion, combines with the ephrin signal to complete fusion in the 
observed time window. 
 The B ephrin cytodomain contains docking sites for a number of signaling 
proteins. Conserved tyrosines can be phosphorylated and function as SH2 domain 
binding sites (233,280). The SH2/SH3 adaptor protein Grb4/Nckß was shown to bind to 
activated ephrin-B1 and signal the disassembly of actin cytoskeletal elements (243). The 
C-terminal end also carries a PDZ domain binding motif (281). Any of these signaling 
motifs may participate in signaling fusion in the palate. However, the Henkemeyer group 
demonstrated that mutation in mice of all known conserved ephrin-B2 tyrosines and the 
PDZ binding domain does not produce CP, even though homozygous deletion of the 
entire cytodomain in ephrin-B2/LacZ mice does (200). This means that ephrin-B2 
contains an as yet unidentified signaling domain that is crucial for palatal seam 
degradation. Previously published work shows that PI3K signaling is required for 
ephrin-mediated fusion (218). This pathway has not previously been associated with 
reverse signaling and represents uncharted territory in the ephrin field. Efforts are 
focused on identification of the ephrin-B domain responsible for the PI3K signal and its 
binding proteins. 
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 PI3K phosphorylates Akt, which in turn activates mTor complexes to induce cell 
migration (282). Activation of mTor is associated with carcinoma EMT and metastasis, 
and so the connection of ephrin-Bs to PI3K provides an explanation for why Eph/ephrin 
signal activation is so often associated with tumor metastases. The PI3K/Akt/mTor axis 
also connects to the EMT transcriptional program. The mTor kinase phosphorylates the 
transcriptional activator Stat3 (210,211), which in turn activates expression of Twist1 
and Snail as part of the EMT transcriptional program (213,283), and both Twist1 and 
Snail are important for palatal fusion (204,284). Although ephrin-B reverse signaling 
was previously shown to associate with both Stat3 and the Groucho repressor of Stat3 
(215,216), very little is known about the potential for reverse signaling to access a gene 
expression program. The connection of ephrin-B signals to the PI3K pathway in 
previous work showed that a connection to transcriptional activation in EMT is 
plausible. The data presented here indicate that such a connection exists and is functional 
during the developmental process of palatal fusion. It also implies that the same 
connection functions in cases of metastatic EMT, and suggests that ephrin-mediated 
pathways may be valid targets for cancer therapies. The ongoing efforts will identify the 
cytoplasmic and nuclear intermediates that connect ephrins to EMT. 
 




Palatogenesis is a very important event during craniofacial development. The 
stages of palatal development traditionally have been defined by the position of the 
palatal shelves in the oral cavity and the level of union at the midline (77). The palatal 
shelves develop from the maxillary prominence of the first branchial arch and initially 
grow vertically along the lateral sides of the developing tongue. At the precise stage of 
embryonic development, the palatal shelves are remodeled to become reoriented to a 
horizontal position above the tongue, and the medial edges of epithelial cells of the two 
palatal shelves meet at the midline. The medial edge epithelia (MEE) of the two opposite 
palatal shelves that arise from the maxillary processes join to form a two- layered medial 
epithelial seam (MES) (77). Then, the epithelial seam disappears and the palate 
mesenchyme becomes confluent. These steps are tightly regulated; failure of palatal 
shelf growth, elevation, adhesion, mesenchymal differentiation and fusion can cause CP 
(67). 
Formation of the medial epithelial seam (MES) by palatal shelf fusion is a crucial 
step of palate development. Complete disintegration of the MES is the final essential 
phase of palatal confluency with the surrounding mesenchymal cells (285).  
The cellular mechanism underlying seam degeneration and the fate of MES cells 
has long been the focus of the field for years. Three major models have been proposed 
for seam degeneration: EMT, migration and apoptosis (22,286). 
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EMT consists of the entire series of events involved in the transition of epithelial 
to mesenchymal cell characteristics (287,288). During EMT, epithelial genes are 
repressed, which allows properties of mesenchymal cells to be activated (288).  
Epithelial and mesenchymal cells have their own unique characteristics and morphology. 
Epithelial cells can be arranged in a single layer, or they can form layers of cells that are 
in close contact with neighboring cells connected by tight junctions, adherent junctions, 
and desmosomes (289). E-Cadherin is the most common adherent protein, while 
occludin, claudins, and zonula occludens (ZO1) are important components of tight 
junctions (290). Desmosomes provide additional strength for intercellular adhesion and 
are structurally similar to adherent junctions. Desmoplakin, plakophilin, and plakoglobin 
are the common desmosomal proteins. All these junctional proteins help epithelial cells 
to remain in a regimented structure (291) and during EMT, these proteins are lost to 
promote significant changes in epithelial cell structure and behavior by changing their 
functional and phenotypic characteristics and acquiring mesenchymal characteristics. 
For almost two decades, it has been understood that MEE degradation and palatal 
fusion requires TGFβ3, a potent inducer of EMT. In mammalian palates, which normally 
fuse on their own, this factor is produced by the palatal tissue itself (34,235), and genetic 
removal of TGFβ3 results in CP. Chicken palates, which do not normally fuse, can be 
induced to fuse by adding exogenous TGFβ3 (234). 
The main purpose of this research project was to investigate a new set of proteins 
involved in palatal fusion, the Eph and ephrins. The first evidence that ephrins play a 
role in palate development came with the linkage of ephrin-B1 mutations to 
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craniofrontonasal syndrome in humans, of which CP is a prominent feature (226). At the 
same time, it was reported that deletion of ephrin-B1 in cranial neural crest cells in mice 
caused craniofacial deformities, including CP (223). The fact that these defects resulted 
from cell-autonomous ephrin-B1 deletion suggested that ephrin-B1 reverse signaling is 
important for palate formation. 
The expression of Ephs and ephrins in embryonic palate was analyzed, using 
LacZ indicator mouse lines (Figure 3-1). It was found that ephrin-B2 and EphB2 were 
expressed specifically in the MES immediately prior to and during its degradation (229). 
Also, EphB2 was expressed in the palatal MEE in the absence of TGFβ3. EphB2 protein 
expression levels in the palates of TGFβ3 knock out mice were comparable to those in 
wild type mice (Figure 4-3). This suggested that ephrin signaling contributes to palatal 
EMT and fusion. 
Also, it was found that fusion of the chicken palates occurred by adding 
EphB2/Fc, even without adding the TGFβ3 that is normally required for fusion. This 
confirmed that EphB2 can indeed act to induce fusion. Furthermore, it was demonstrated 
that ephrin-B reverse signaling is necessary for palate fusion when the unclustered 
EphA4/Fc protein was added. EphA4/Fc promiscuously binds all B-ephrins without 
activating signaling acting as competitive inhibitor, blocking fusion even in the presence 
of TGFβ3.  
TGFβ3 requires the activity of phosphatidylinositol 3-kinase (PI3K) for fusion 
(203), and the same is true for ephrin reverse signaling, as palates stimulated in culture 
with EphB2/Fc did not fuse in the presence of the PI3K inhibitor LY294002. The 
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chicken palate findings show that ephrin signaling is downstream, or at least independent 
of TGFβR signaling. The EphA4/Fc-blocking experiments demonstrated that the ephrin 
requirement is conserved between mouse and chick. However, blocking antibodies 
against TGFβ3 inhibit mouse palate fusion, and genetic ablation of TGFβ3 in mice 
yields cleft secondary palate (34,40,235,265). Thus, endogenous ephrin signals are not 
sufficient to compensate for loss of TGFβ3.  
In the final set of experiments, two chemical inhibitors were used: anti-TGFβ3 
and the TGFβr kinase inhibitor (SB 431542) with or without EphB2/Fc. SB 431542 is a 
strong and selective inhibitor of TGF-β superfamily type I a receptor-like kinase (ALK) 
receptors. Inhibition of TGF-β signaling is known to induce the repression of epithelial 
fate. The results were consistent in both experiments, control palates in these 
experiments fused normally over the three-day time window, although fusion was 
incomplete in the posterior region. The groups treated with the anti-TGFβ3 antibodies  
and SB 431542 abolished MES degradation and palatal fusion such that the epithelial 
layers in the MES remained almost entirely intact. In both treatment groups, addition of 
recombinant EphB2/Fc restored widespread, but not complete, seam degradation and 
largely rescued fusion (Figure 4-1 and Figure 4-2). These data demonstrated that 
exogenous activation of ephrin reverse signaling was capable of causing MES 
degradation and palatal fusion in the absence of a TGFβ signal. The EphB2 treatments 
did not completely rescue fusion in TGFβ-blocked palates, and this observation could be 
explained by an insufficiency of ephrin reverse signaling to activate a specific part of the 
fusion program, such as an apoptotic activity that removes remaining MEE cells.  
  80 
The MEE cells were isolated and their comportment was investigated after 
activation of the ephrin reverse signal.  MEE cells grown to confluence exhibit the 
characteristics of epithelial cells. Packed, cuboidal cells joined in a sheet by desmosomes 
and tight junctions. E-cadherin, desmoplakin, and plakoglobin are among the proteins 
that are highly expressed in these epithelia-specific junctions.  After 48 hrs of exposure 
to clustered EphB2/Fc, the expression of these proteins disappeared. At the same time, 
fibronectin and vimentin, both fibroblast markers, rapidly increased. EphB2/Fc-treated 
cells assumed a looser, mesenchymal shape and became motile.   
In a scratch-wound assay on monolayers of the same MEE cells treated with 
EphB2/Fc showed an increased number of cells moved into the cleared scratch area over 
a 48 h period; whereas, control cells moved in fewer number over the same period of 
time.  By 48 h of treatment, a six-fold increase was observed in motile cell number in 
EphB2/Fc cultures. 
The results for gene expression were consistent with the changes expected for 
ephrin reverse signaling in activation of the EMT program. The transcription factors 
Snail and Sip1 are upregulated during developmental EMT and repress E-cadherin 
expression (249). Therefore, the mRNA levels were quantified using real-time PCR of in 
MEE cells after 48 h of EphB2/Fc treatment. Snail and Sip 1 increased, E-cadherin 
mRNA decreased when compared with the controls. Twist1 mRNA increased slightly; 
however, the change was significant. The results were consistent with a role for ephrin 
reverse signaling in activation of the EMT gene expression program.  
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The finding of PI3K involvement in ephrin reverse signaling provides a 
connection to this migration mechanism. PI3K signals to Akt, which activates the mTor 
complex, leading to migration of cancer cells. This pathway is frequently activated in 
malignancies, and inhibition of the mTor complex proteins Raptor and Rictor retards 
cancer cell invasiveness and suppresses the EMT required for metastasis (282).  This 
mechanism may control the EMT and migration of epithelial cells during palatal fusion 
(Figure 2-2). 
The discovery that EphB2 treatment both induces fusion and initiates EMT in 
MEE cells independently of TGFβ3 reinforces the view that EMT is a part of the fusion 
mechanism.  Thus, Ephrin-B signaling could induce apoptosis in other systems (279). It 
also implies that the same connection functions in cases of metastatic EMT, and suggests 
that ephrin-mediated pathways may be valid targets for cancer therapies.  
Understanding normal palate development as well as aberrant pathways involved 
in abnormal palate development is crucial to allow us to better develop therapeutic 
modalities to treat patients. Identifying the major pathways involved and manipulating 
those pathways prior to birth would represent a monumental step to prevent the primary 
and many secondary complications caused by CLP.  
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Figure 1-1. Schematic drawing showing coronal view of a normal palate shelf and key 
stages of mouse palatal development. At E12-E13 days in the mouse gestation, the palatal 
shelves grow downward along the tongue (t). At E13-E13.5 days, the palatal shelves become 
elevated above the tongue. At E14.5, the palatal shelves adhere to each other in the midline. 
After E15.5 days, the MES completely degrades, and the palate fuses. 
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Figure 1-2. Comparison of the morphogenesis of the upper lip with that of the palate (D-F). 
After the bilateral maxillary processes (max) fuse externally with the inter-maxillary segment, 
the resulting epithelial seam (arrow, B) gives rise to mesenchyme (arrowhead, C) to produce a 
confluent lip. At a later time, the palatal shelves arising internally from the maxillary processes 
fuse with each other (arrows, D) and with the nasal septum (ns) above them, creating an 
epithelial seam that transforms to mesenchyme (arrowheads, E) to produce the confluent palate 
(arrowheads, F). p, sloughed periderm cells (32). 
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Figure 1-3. Diagram showing the relationship between the NC cartilages and the 
transpalatal suture. A) Dotted lines indicate cut lines for removing the palate from the embryo 
and the NC cartilage from above the sutures. (B-E) Micrographs of parasagittal sections of foetal 
rat heads show the pre-natal development of TP sutures. (B) At E16, NC cartilages (arrows) can 
be seen directly above the presumptive TP suture region (in box). (C) High-power micrograph of 
the region in the box, showing the advancing palatal plate of the maxilla and horizontal plate of 
the palatal bone (asterisks) on either side of the presumptive TP suture (between arrows). (D) At 
E18, the advancing bone fronts (asterisks) begin to overlap one another, creating a highly 
cellular suture blastema (between arrows). (E) By E20, an elongated TP suture (between arrows) 
continues to form as the bone fronts proceed to overlap one another. A, airway; B, shelves of 
maxillary bones; MP, midpalatal suture; NCC, nasal capsular cartilage; O, oral cavity; TP, 
transpalatal suture (143). 
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Figure 2-1. Ephs and ephrins in fusing palate. (A) Steps in mammalian palatal fusion. Palatal 
shelves of mesenchyme ensheathed in a two-cell thick epithelial layer elevate over the tongue 
and grow to midline. This happens beginning at about embryonic day 12.5 in the mouse. At 
e14.5, the epithelial cells adhere, migrate into the mesenchyme and/or die, leaving a confluent 
mesenchymal shelf. (B) Summary of published patterns of Eph and ephrin expression in the 
palate just before and during fusion. 
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Figure 2-2. Two proposed models of ephrin-B reverse signaling in palatal EMT based on 
current evidence. Pathway 1 places ephrin signaling downstream of TGFβ3 signaling such that 
TGFβ3 stimulates expression of EphBs and/or ephrin-Bs, leading to activation of PI3K 
signaling. In pathway 2, TGFβ3 and ephrin-B signaling act in parallel to stimulate PI3K 
together.  
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Figure 3-1. EphB2 and ephrin-B2 expression in fusing palate epithelium. Day 14.5 embryos 
from mice harboring: (A) the EB2/LacZ chimeric allele or (B) the LacZ knock-in to the EphB2 
locus were sectioned coronally and stained with X-gal. Counter stain is Nuclear Fast Red. βgal 
expression was found in the palate epithelium, suggesting a role in adhesion and/or fusion. Note 
the breakup and dispersion of EB2/βgal during EMT. 
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Figure 3-2. Eph and ephrin effects on palate fusion. Palatal shelves were dissected from eight 
day old chicken embryos and cultured in contact on a support for 72 h in the presence of specific 
treatments, as indicated. Tissues were fixed, paraffin processed, and sectioned. Shown are 
representative H&E stained sections from each treatment. Note the darkened epithelial layer that 
disappears as fusion proceeds. H&E stained sections from anterior to posterior were scored on 
for fusion on a scale of 1 to 5 at anterior, middle, and posterior points and these scores averaged 
to yield the mean fusion score (MFS) shown.  
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Figure 3-3. Ephrin dependence of mouse palate fusion. Embryonic day 14.5 mouse palates 
were cultured in the presence of unclustered EphA4/Fc soluble recombinant protein or IgG Fc 
control protein as described in the text. Tissues were fixed, paraffin processed, and sectioned. 
Shown are representative H&E stained sections from each treatment. H&E stained sections from 
anterior to posterior were scored on for fusion on a scale of 1 to 5 and these scores averaged to 
yield the mean fusion score (MFS) shown. Values are ±SEM for n=14 palates over four 
independent experiments. Magnification is 200×. 
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Figure 3-4. Effect of PI3K inhibition on Eph-induced palate fusion. Chicken palates were 
grown with the treatments indicated under the conditions described in the text. Samples grown in 
TGFβ3 or EphB2 alone fused almost completely. Addition of the PI3K inhibitor LY294002 
abrogated fusion with either TGFβ3 or clustered EphB2/Fc. Shown are H&E stained examples of 
each group with n=16 to 19 for each group from 3 independent experiments. Mean fusion score 
(MFS) for each is shown ± SEM. Magnification is 100×. 
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Figure 3-5. Model of ephrin and TGFβ3 signal transduction in palate fusion. Ephrin and 
TGFβR signals intersect at a point upstream of PI3K, which is required for fusion. Other 
possible pathways from eprhin-Bs that do not go through PI3K are not diagrammed. Known 
possible effectors or ephrin-Bs in reverse signaling are described in the text. Signals from Eph 
RTKs that induce partial fusion are unknown. 




Figure 4-1. Ephrin reverse signaling induces palatal fusion without TGFβ3. Mouse E13.5 
palatal shelves were dissected and grown with their medial edges in contact for 72h in the 
presence of treatments as indicated. All samples received either EphB2/Fc or IgG Fc protein at 5 
µg/ml. Tissues were then fixed, paraffin-embedded and sectioned in the coronal orientation from 
anterior to posterior for histological analysis. Anterior, medial, and posterior regions were scored 
for fusion based on a one to five scale. Values shown are mean±SEM with n=12 to 18 palates for 
each group pooled from three independent experiments. (A) Control palates were treated with 
IgG Fc control protein and fused normally, with a slight decrease in posterior score indicative of 
the incomplete fusion commonly observed in some embryos during the 72h experimental period 
(MFS= 4.5 anterior, 4.6 middle, 3.0 posterior). Palates treated with 10 µM anti-TGFβ3 failed to 
fuse (MFS= 1.4 anterior, 2 middle, 1.3 posterior) and displayed intact MES. Palates treated with 
anti-TGFβ3 antibody+EphB2/Fc fused substantially better, especially in the middle region, 
displaying significant MES degradation (MFS= 2.6 anterior, 3.9 middle, 2.6 posterior). (B) 
Example H&E stained sections from each experimental group in A.  




Figure 4-2. Ephrin reverse signaling induces palatal fusion without TGFβr. (A) 
Experimental conditions were the same as in A, except that the SB431542 inhibitor of the TGFβr 
kinase was used at 25 µM instead of anti-TGFβ3. IgG Fc control palates fused normally (MFS= 
3.5 anterior, 4.7 middle, 3.4 posterior), and SB431542 abolished fusion (MFS= 1.3 anterior, 1.7 
middle, 1.1 posterior). EphB2/Fc largely rescued fusion in the presence of kinase inhibitor 
(MFS= 2.0 anterior, 3.8 middle, 3.1 posterior). (B) Example H&E stained sections from each 
experimental group in C. Differences between antibody or inhibitor treated groups and their 
corresponding EphB2/Fc treated groups were statistically significant as determined by Mann 
Whitney U Test (**p<0.001). 
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Figure 4-3. TGFβ3 is not required for EphB2 expression. (A) Sections of palates from wild 
type and TGFβ3 knockout mice were stained with antibody against EphB2. Staining (reddish-
brown, DAB) is apparent in the MEE with both genotypes. (B) Mouse palatal MEE cells were 
grown in the presence of the indicated doses of either 10 µM TGFβ3 or 5 µg/ml EphB2/Fc for 
48 h before being harvested for Western analysis with anti-TGFβ3 or anti-EphB2. 
UN=untreated; IgG=IgG Fc treated control. TGFβ3 treatment did not increase EphB2 levels 
while EphB2 treatment increased TGFβ3 levels modestly. Thus, the ability of TGFβ3 to cause 
palatal fusion cannot be explained by simple stimulation of EphB expression. 
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Figure 4-4. Ephrin reverse signaling causes EMT in mouse palatal MEE cells. Embryonic 
mouse MEE cells were cultured for 48 h in either IgG Fc or EphB2/Fc protein at 5 ng/ml, then 
fixed and processed for immunofluorescent detection of epithelial or mesenchymal markers. (A) 
Expression of the epithelia-specific cell junction markers E-cadherin, demosplakin, and 
plakoglobin (green) virtually disappeared after 48 h of EphB2/Fc treatment. (B) Expression of 
the mesenchymal markers fibronectin (green) and vimentin (red) increased dramatically after 48 
h of EphB2/Fc exposure while expression of epithelia-associated proteins E-cadherin (red) and 
Z01 (green) essentially disappeared. 
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Figure 4-5. Expression of the mesenchymal markers fibronectin (green) and vimentin (red) 
increased dramatically after 48 h of EphB2/Fc exposure while expression of epithelia-associated 
proteins E-cadherin (red) and Z01 (green) essentially disappeared. 
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Figure 4-6. Ephrin reverse signaling induces migration of mouse palatal MEE cells. (A) 
Embryonic MEE cells were grown to confluence and then scratched with a needle to create a 
cleared area with uniform borders. The cells were treated with IgG Fc or EphB2/Fc for 48 h. (B) 
The number of cells that migrated across the borders into the cleared area was counted at 24 and 
48 h. The change in the number of cells was determined by comparison to control (IgG Fc) and 
plotted as actual numbers of migrating cells (mean±SD.; n=3; *P<0.005 compared with controls 
AP-value of ≤0.05 was considered signiﬁcant. The one-way ANOVA indicated that the values 
differ signiﬁcantly across the treatment groups. All EphB2 treatment (time dependent) differed 
signiﬁcantly (*P≤0.005) from the control groups (IgG Fc). 
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Figure 5. Ephrin reverse signaling induces EMT-associated gene expression in palatal 
MEE cells. RNA was harvested from mouse palatal MEE cells cultured for 48 h with 1, 2, or 5 
µg/ml EphB2/Fc as indicated. Quantitative real time PCR analysis showed that messages for 
Snail, Sip1, and Twist1 were all significantly increased by EphB2/Fc treatment, demonstrating 
that ephrin reverse signaling activated expression of EMT-associated transcription factors. The 
change in mRNA levels was determined by comparison to control (IgG Fc) and plotted as fold 
change/s (mean±SD.; n=3; *P<0.005 compared with controls; AP-value of ≤0.05 was considered 
signiﬁcant. The one-way ANOVA indicated that the values differ signiﬁcantly across the 
treatment groups. All EphB2 treatment (dose dependent) differed signiﬁcantly from the control 
groups (IgG Fc) **P<0.0005. 
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APPENDIX B TABLES 
Table 1. Syndromic Genes Associated with Cleft and Palate 
 
SYNDROME CLINICAL FEATURES GENES REFERENCE 
Apert Syndrome 
(AS) 






AR; hypothyroidism, athyroidal, CPO, 






AD; pseudocleft of the upper lip resembling a 
poorly repaired cleft lip. 
TFAP2A  (116,299)  
Down syndrome 
(DS) 











AD; triad of ectrodactyly, ectodermal 





Disorder characterized by a pattern of minor 
facial anomalies, prenatal and postnatal 










Oculo auricular vertebral dysplasia; AD;   
incomplete development of the ear, nose, soft 









AD; lymphedema of the limbs, double rows of 






AR disorder; Hypogonadotropic 







dysplasia (ED4)  
AR; unusual facies, dental anomalies, 







 AD; triad of micrognathia, glossoptosis, and 









AR; defects in cholesterol biosynthesis, 
growth retardation, dysmorphic facial features 





AD; midface hypoplasia, micrognathia, Pierre 
Robin sequence, retinal detachment and early 







AD ; craniofacial deformities such as 
downward slanting eyes, micrognathia, 
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SYNDROME CLINICAL FEATURES GENES REFERENCE 
van der Woude 
syndrome (VDWS) 
AD;  cleft lip palate, distinctive pits of the 









AD ; cleft palate, heart defects, abnormal 






Unnamed syndrome CLP and hereditary diffuse gastric cancer CDH1 (93) 
Unnamed syndrome Chromodomain helicase DNA-binding 
proteins; CLP in Charge syndrome 
CHD7 (324,325) 
Unnamed syndrome Bilateral CLP, colobomas of the optic nerve 
and retina, agenesis of the corpos callosum. 
Dysphagia, reduced esophageal peristalsis 
PAX 9 (116,326) 
Unnamed syndrome X-linked mental retardation and CLP PH8 6, (327)  
Unnamed syndrome Holoprosencephaly 7, a spectrum of forebrain 




Unnamed syndrome CPO, craniofacial anomalies, osteoporosis, 
and cognitive defects 
SATB2 (116,330) 
Unnamed syndrome Holoprosencephaly, a spectrum of anomalies 
ranging from severe (cyclopia) to subtle 
midline assymetries. CLP part of the spectrum 
SHH (116,315)  
Unnamed syndrome Anomalies with most features of 
DiGeorge/velocardiofacial  syndromes: CPO, 
thymus and parathyroid gland hypoplasia, 
vertebra, facial and cardiac outflow 
anomalies. 
TBX1 6, (331) 
Unnamed syndrome X-linked CPO and ankyloglossia TBX22 6, (73,74)  
Unnamed syndrome Cardiovascular, craniofacial, skeletal, and 
cognitive alterations,bifid uvula and or/CPO 
TGF Beta 
receptor 
6, (332)  
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Table 2. Non Syndromic Genes: Interaction Effects of Genes and Environmental Risk 
Factors on Oral Clefts. 
 
GENE FUNCTIONAL ROLE RISK FACTOR REFERENCE 
Cytochrome P450 
Proteins (CYP) 
CYPIA1, CYPIA2,  
CYPIB1 CYP2E1 
Highly polymorphic, having multiple 
functional alleles; Role in detoxification; 
metabolism of endogenous morphogens 
in the developing fetus. 







Class of proteins that catalyze the 
hydration of chemically reactive 
epoxides into their corresponding 
dihydrodiol products.  
  
EPHX Plays an important role in both the 
bioactivation and detoxification of 
exogenous chemicals  such as PAHs, 







EPHX1  Y113H Variant of EPHX 1 found in the fetus 










Families of dimeric phase II enzymes 
that catalyze the conjugation of reduced 
glutathione with electrophilic groups of 
a wide variety of environmental agents. 
  
GSTM1 Major gene detoxifying PAHs and 










Expressed in a variety of tissues/organs  
such as erythrocytes, lung, kidney, 
brain, skeletal muscles, heart, and small 
intestine; elevated expression profile at 












Major gene detoxifying PAHS; 
involvement in variety of disorders and 
cancers. Major enzyme involved in the 
inactivation of cigarette smoker’s 
metabolites; most important isoform at 



















Mechanism that maternal smoking may 
affect embryonic development due to 
the production of carbon monoxide, 
which interferes with oxygen transfer to 
the placenta, or nicotine, which 
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hypoxia.  





N-conjugation of arylamine by the 
action of N-acetyltransferases (NATs), 
UDP glucoronosyltransferases (UGTs), 




 (NAT 1) 
Expressed in many tissues such as 
erythrocytes, bladder, lymphocytes, 








Pseudogene identified, which is located 





Expressed in the liver and epithelial 











Metabolism of folate by reducing 
methylenetrahydrofolate, primary donor 
for methionin synthesis. 
 

















Flavoenzyme that catalyzes two electron 
reduction of quinine compounds to 
hydroquinone and is inducible by 
oxidative stress, dioxin, and PAHS 






SULT1A1   
 
Catalyzes transfer of the sulfonate group 
from the active sulfate to a substrate to 












Catalyzes conjugation reactions where 
hydrophobic chemicals are transformed 
into water-soluble compounds. Potential 








DEVELOPMENTAL GENES FOR ORAL CLEFTS 
Transforming Growth 
Factor A (TGF a) 
 
Transmembrane protein expressed at the 
medial edge of the epithelium (MEE) of 
fusing palatal shelves. Its receptor 
epidermal growth factor (EGFR) is 
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Transforming growth 
Factor b-3 (TGF b3) 
 
Regulator of many biological processes 
such as proliferation, differentiation, 












Transcriptional repressor important in 












Similar to MSX1; rare cause of isolated 





Pericentric inversion disrupts a gene 
(ACOD4) on chromosome 4q21 that 
codes for a novel acyl-CoA desaturase 
enzyme that occurs in a single two-
generation family with CL. 
 (359) 
Retinoic acid receptor 
( RAR) 
Odds ratios for transmission of alleles at 
THRA1 were significant when ethnic 





CHD7  Chromodomain helicase DNA-binding 
proteins. 
 (360) 
ESR1 Ligand-activated TF estrogen receptor.  (361) 
FGF/ FGFR families   
FGF8 FGF3 FGF10 
FGF18 FGFR1 
FGFR2 FGFR3 
Expressed during craniofacial 
development and can rarely harbor 




SPRY1/SPRY2 Loss of function mutations in FGFR1 
cause a syndromic form of clefting. 
 (363) 
TBX10 Ectopically expressed in dancer cleft lip 
and palate mutant mice. 
 (363) 
GABRB3  b3 subunit of GABA receptor CLP.  (85),(364),(116)  
GLI2 Mutations in GLi2 cause 
holoprosencephaly-like features with 
cleft lip and palate. 
 (363) 
ISGF3G Similar to IRF6.   (363) 
 
OTHER CANDIDATE GENES  
SKI, FOXE1,  JAG2, 
LHX8  
Rare causes of isolated cleft lip with or 
without cleft palate 
 (363) 
 
